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ABSTRACT 
 
ADENO-ASSOCIATED VIRAL VECTOR-DRIVEN EXPRESSION OF 
COAGULATION PROTEINS FOR TREATMENT OF  
HEMOPHILIAS AND CANCER 
 
Julie M. Crudele 
 
Valder R. Arruda 
 
 
Treatment of hemophilia, which involves infusion of the missing clotting factor, is often 
hindered by the development of neutralizing antibodies to the replaced clotting factor.  
We utilized liver-directed AAV gene therapy to tolerize outbred hemophiliac dogs with 
pre-existing anti-factor VIII and IX antibodies and to treat their underlying hemophilia.  
Additionally, we sought to shed light on the immunologic mechanisms responsible for 
this tolerization.  Staining for CD4+CD25+FoxP3+ T cells and cytokine profiles of treated 
dogs suggest that induced Tregs are at least partially responsible for inducing and 
maintaining tolerance. 
 
The second part of the dissertation attempts to determine the underlying mechanism of 
the known anti-metastatic effects of activated protein C (aPC).  We again utilized liver-
directed AAV gene therapy to tease apart the anticoagulation and cytoprotective effects 
of aPC, as these were the most likely candidates based on available literature, in the 
B16F10 murine model of metastatic melanoma.  Upon finding, however, that neither of 
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these functions were involved in aPC’s cancer protection and that zymogen PC is even 
more protective, we endeavored to find the novel mechanism through which the protein C 
pathway can modulate tumor progression.  While the mechanism has not been found, a 
number of potential candidates and receptors have been eliminated, including 
involvement of PAR-4, EPCR, and a potential integrin binding site.  We also demonstrate 
that it is not tumor growth, but rather a step in the metastatic pathway that is inhibited. 
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CHAPTER 1 
INTRODUCTION 
 
 
I. Adeno-associated viral vector gene therapy 
One in every 200 live-born babies will have a monogenetic disorder—such as cystic 
fibrosis, hemophilia, or sickle cell anemia—of which there are more than 6000 known 
diseases. 1  Many more will be affected by polygenic and/or environmentally-influenced 
pathologies, including Alzheimer’s disease, heart disease, diabetes, arthritis, and cancer.  
Unfortunately, treatment options are not always available or successful for the wide-
range of genetic diseases.  When therapies do exist, they can involve life-long and often 
expensive pharmaceutical, surgical, and/or life-style interventions and are usually 
focused on ameliorating the consequences of the genetic defect, rather than correcting the 
underlying problem. 
 
Gene therapy is a potential treatment for many of the monogenetic diseases where the 
culprit gene has been identified and for multifactorial inherited and acquired disorders 
where a known gene product would help ameliorate disease phenotype.  Regulation of 
expression, correction or de novo expression of a gene is achieved by packaging the 
required therapeutic transgene cDNA into a delivery vector—often a virus, liposome, or 
plasmid DNA, which is used to transduce target cells.  This can be done directly by in 
vivo delivery of vector or indirectly ex vivo, in which cells are harvested, transduced in 
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vitro and then returned to the patient.  Given that the treatment is typically meant to lead 
to production of a novel protein, there is a risk of an inadvertent immune response against 
the transgene and the targeted cells, especially in instances where the underlying genetic 
mutation requiring correction is an early stop codon, frame shift, or large inversion or 
deletion.  With missense mutations, conversely, patients are often already tolerized to 
most—if not all—of the protein epitopes, so the risk of an immune response is 
diminished.  Furthermore, there is also the possibility of a reaction against the vector, 
which can lead to destruction of the transduced cells 2, flu-like symptoms 3, cytokine 
storm, and even death 4.  Thus, vectors must be chosen carefully based on the desired 
target cells and intended purpose, with consideration given to potential negative 
outcomes. 
 
Adeno-associated virus (AAV) 5 is a small, non-enveloped parvovirus (family 
Parvoviridae, genus dependovirus) that has been isolated from numerous species, 
including humans.  It has a 4.7-kb, single-stranded DNA genome that converts to double-
stranded DNA after infection. 6  The relatively small genome consists of only two genes 
encoding replication (rep) and capsid (cap) proteins, framed by inverted terminal repeats 
(ITRs).  With so few genes encoded, AAV is naturally replication defective and requires 
the machinery of a “helper” virus such as an adenovirus or herpes virus to advance to the 
lytic stage. 5  In the absence of such help, wild type AAV persists in a latent state by 
integrating into the human host genome, usually at a specific site on chromosome 19. 7, 8  
This integration is rep-directed, however; so in its recombinant vector form—with rep 
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and cap deleted—the genome persists as concatemers in an extra-chromosomal state. 8   
 
The rarity of integration events with AAV vectors is associated with a favorable safety 
profile by decreasing the risk of tumor-suppressor disruption or oncogene activation, both 
of which can lead to cell transformation and cancer.  However, persistence in dividing 
cells is limited by its episomal state, and thus AAV is best suited for transduction of 
postmitotic cells when long-lasting expression is sought.  AAV is not known to cause any 
illnesses in humans, despite a high prevalence of seropositivity in humans. 9  Therefore, 
recombinant AAV is a promising gene therapy vector due to its nonpathogenic nature, 
ability to transduce non-dividing cells, serotype-dependent targeting of a wide variety of 
cell types, and long-term genomic persistence in non-dividing cells.  
 
There are two major limiting factors to AAV’s potential efficacy as a gene therapy 
vector.  The first is the limited packaging capacity.  By most counts, AAV vectors cannot 
efficiently package more than 5 kb of DNA 10, which greatly limits the transgenes, 
promoters and enhancers that can be used.  Secondly, while minimally immunogenic and 
with involvement of the innate immune system limited mostly to TLR-9 11, 12, 13, there are 
still adaptive anti-AAV immune responses that can limit efficacy.  Specifically, anti-
AAV antibodies can inhibit primary in vivo transduction 14 and prevent vector re-
administration, while anti-AAV capsid cytotoxic T cells can lead to destruction of 
transduced cells 2.  Approximately 90% of humans are seropositive for at least one 
serotype of AAV 9, which limits the potential patient population.  However, prevalence of 
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neutralizing antibodies (NAb) varies greatly with serotype: anti-AAV2 NAb are amongst 
the most prevalent because humans are the natural AAV2 host, while anti-AAV5 and 8 
are amongst the least 15.  Unfortunately, anti-AAV2 NAbs can cross react with a number 
of other serotypes.  The cytotoxic CD8+ T cell responses to AAV capsid that can lead to 
killing of transduced cells have been demonstrated in multiple gene therapy clinical trials 
following intravascular or direct intramuscular injection of the vector 16, 17.  To date, 
limited experience with intravascular delivery of AAV has shown that capsid-associated 
immunogenicity is transient and lasts only until a relatively rapid vector capsid clearance, 
is vector-dose dependent, and is potentially controlled with a short course of mild 
immunosuppression.  Interestingly, sub-retinal injection of AAV vectors in early phase 
clinical trial is not influenced by the presence of NAb to AAV capsid, even for vector re-
administration, or by the cytotoxic T cell responses 18, 19, 20. This is probably due to the 
immune privileged status of the eye. 
 
Despite these challenges, adeno-associated viral vector gene therapy has the potential to 
treat a wide range of monogenetic and multifactorial diseases. 
 
II. Hemophilia and the immune system 
Hemophilia A and B, monogenetic diseases and the focus of the second and third 
chapters, are caused by mutations in the X-linked genes encoding clotting factor (F) VIII 
or IX, respectively.  Patients are classified based on the severity of disease 21 (Table 1.1), 
which is directly related to the residual clotting factor activity, with patients with severe 
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hemophilia retaining less than 1% of normal activity levels of FVIII or FIX.  Notably, an 
increase in sustained activity levels to just above 1% can have a profound impact on the 
disease phenotype and a patient’s quality of life, with levels over 5% almost entirely 
ameliorating day-to-day symptoms.  Mild and moderate hemophilia are usually caused by 
missense or late nonsense mutations, while large deletions, rearrangements, early stop 
codons or frame shifts, partial duplications, or inversions typically result in severe 
disease.  The most common mutation, affecting up to 40% of patients with severe HA, is 
an inversion breaking intron 22 and reversing the first 22 exons of FVIII 22.  Patients with 
the intron 22 inversion or some of the other severe mutations have no circulating FVIII or 
FIX, depending on the affected gene, in their bloodstream (described as negative for 
cross reactive material; CRM-). 
 
1 in 5,000 males born worldwide—independent of race—will suffer from hemophilia A 
(HA), while hemophilia B (HB) affects 1 in 30,000 males.  Current standard-of-care 
treatment for hemophilia consists of replacing the missing or mutant factor via 
 
 
 
 
Table 1.1 Hemophilia severity classifications 
Severity 
classification 
Residual 
factor activity, 
% of normal 
Common  
phenotype 
Bleeding 
frequency 
Prevalence 
Severe <1% 
Spontaneous bleeding; 
joint bleeding 
Weekly 
~60-70% of HA 
~50% of HB 
Moderate 1-5% 
Bleeding with slight injury; 
may have joint bleeding 
Monthly 
~15% of HA 
~30% of HB 
Mild >5% 
Bleeding with major 
trauma or surgery; rarely 
has joint bleeding 
Potentially 
never 
~25% of HA 
~20% of HB 
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intravenous infusions of wild type protein concentrates given on-demand in response to 
bleeds or, to patients in the developed world, prophylactically.  Sources of factor include 
recombinant protein and protein purified from pooled donor plasma. 21  In the United 
States, where the standard of care is prophylactic administration of factor, the cost of care 
for a single hemophilia A patient is about $200,000 per year depending on the therapeutic 
regimen and body weight of the patient. 23 
 
A major treatment complication facing hemophilia patients in the industrialized world 
today is the development of polyclonal antibodies, clinically termed inhibitors, that block 
the therapeutic activity of the infused factor.  Inhibitors will develop in about 20-30% of 
individuals with severe HA and 5-10% of individuals with mild or moderate HA, while 
inhibitor formation is closer to 1-3% of individuals with HB 24, 25.  While it is not 
currently possible to predict with certainty which patients will develop inhibitors 26, 27, 28, 
there are associated risk factors.  Underlying mutation correlates strongly with risk.  For 
HA, incidence of inhibitors is greater than 30% in patients with large deletions, nonsense 
mutations, and large inversions, but only 8% in patients with missense mutations 29.  
Additionally, the chance that a patient will develop inhibitors increases when he is of 
non-Caucasian descent, has a family history of inhibitors, is first exposed to factor 
concurrently with surgery or trauma, or is treated on-demand rather than prophylactically 
28, 29, 30.  Polymorphisms in the TNF-α and CTLA-4 genes and the IL-10 promoter are 
also associated with higher risk of inhibitors in HA (no such data exists for HB due to 
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limited patient numbers). 31, 32, 33  In severe hemophilia, onset usually occurs within the 
first 20 factor infusions. 26, 28 
 
Patients with inhibitors are grouped based on inhibitor titer (defined as Bethesda Units, 
BU, where 1 BU inhibits 50% activity of normal plasma) and treated accordingly.  Those 
with >5 BU are classified as high-responders while those with 0.6-5 BU are low-
responders; <0.6 BU is considered negative for inhibitors. 34  Low-responders are treated 
with higher or more frequent doses of factor in order to overwhelm the circulating 
antibodies and establish hemostasis.  In high-responders, antibodies can be temporarily 
removed from the plasma by plasmapheresis to allow for treatment with factor.  This, 
however, is a short-term solution reserved for life-threatening situations. 34, 35  Instead, 
hemophilia patients with high-titer inhibitors in wealthy countries are typically treated 
with bypass agents, including activated FVII or activated prothrombin complex 
concentrates, which circumvent the need for FVIII or FIX in the clotting cascade.  
Unfortunately, bypass agents, which are extremely costly, are not as efficacious as 
FVIII/FIX replacement at alleviating bleeding 36, so patients suffer from higher joint 
damage, lower quality of life, and shorter lifespans 34, 37, 38, 39, 40.  Thus the presence of 
inhibitors is associated with both increased morbidity and mortality. 
 
The best course of action for inhibitor patients is tolerization to FVIII or FIX through 
intensive immune tolerance induction (ITI) protocols.  ITI is effected through frequent 
(typically daily), uninterrupted factor infusions 41, 35, 42, sometimes coupled with 
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immunosuppression for HB patients refractory to ITI 43, 24 despite the lack of evidence 
that this increases success rates, followed by enduring prophylactic infusions once 
tolerization is established to prevent anamnestic responses upon re-exposure to FVIII or 
FIX concentrate.  The average time to tolerance induction in HA ranges from 4 to 12 
months, but 48 months of treatment is required for 90% of HA patients to be successfully 
tolerized 26, 27.  ITI success rates vary from study to study, usually ranging from 55-80% 
for HA and 10-60% for HB, with high-responders requiring longer periods on ITI and 
demonstrating higher rates of failure.  Patients are more likely to be tolerized if they have 
had fewer factor infusions between the time of inhibitor development and initiation of 
ITI, lower titer inhibitor at the time of ITI initiation (<10 BU), and lower peak inhibitor 
titer 26, 27, 44, 41.  Additionally, in the case of FIX inhibitors, ITI carries a risk of 
anaphylaxis and nephrotic syndrome, both of which decrease the likelihood of successful 
retolerization. 24  It costs approximately 1 million US dollars to tolerize patients through 
high-dose, frequent factor infusion 45, though this is significantly less than the cost of care 
via life-long bypass agents.  Fortunately, relapse rates for HA are <5% 27.   
 
The dependency of inhibitor development on CD4+ T cells has been shown in 
hemophiliac patients with advanced AIDS whose inhibitor titers fell with CD4+ T cell 
counts 46 and experimentally in mice demonstrating CD4+ T cell proliferation during 
onset of inhibitors 47.  Additionally, inhibitor development in mice was prevented and 
pre-existing inhibitor production diminished when CD4+ T cell activation was blocked by 
knocking out B7-2 or treating with CTLA4-Ig 48.  While these studies indicate that 
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inhibitor development is CD4+ T cell dependent, not much else is known about the 
mechanisms through which they arise.   
 
Furthermore, despite over 30 years of clinical practice, the underlying mechanism by 
which ITI is successful remains incompletely understood and is likely to be complex.  
One study established that high-dose FVIII infusions in HA mice with inhibitors leads to 
irreversible inhibition of FVIII-specific memory B cells in a T cell-independent fashion 
49.  While this was an important discovery explaining ablation of existing FVIII responses 
during ITI, it does not explain how tolerance is maintained long-term.  In humans, Tregs 
have been implicated by an in vitro study in which CD4+CD25+ T cell-depletion of 
PBMCs from healthy individuals resulted in an enhanced CD4+ T cell proliferative 
response to FVIII 50.  Additionally, CD4+ T cells isolated from the peripheral blood of a 
mild HA patient with inhibitors were more responsive after stimulation with FVIII upon 
Treg depletion 51.   
 
There is evidence that, in the right setting, gene therapy can actually induce 
immunological unresponsiveness to a therapeutic protein, with the advantage that the 
protein can be continuously expressed, rather than the stop-and-start levels provided by 
pharmaceuticals.  For example, liver-directed gene therapy utilizing AAV vector can 
effectively tolerize animal models against the transgene 52, 53, 54.  The mechanisms of 
tolerance in this setting have been well studied in mice, involving CD4+ T helper cell 
clonal deletion, anergy, and CD4+CD25+FoxP3+ Treg-mediated suppression 52, 55, 56, 57.  
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However, data elucidating the mechanisms of tolerance by gene therapy in large HA 
animal models and by intravenous protein infusion in humans is lacking. 
 
III. Cancer metastasis and coagulation 
It has long been known that cancer and coagulation are inextricably linked.  Cancer 
patients are at a higher risk of developing thrombosis, and unprovoked venous 
thromboembolism (VTE) can actually be an indicator of undiagnosed cancer in some 
cases 58, 59.  The mechanisms through which malignant neoplasms initiate coagulation are 
debated and likely numerous and variable.  There are data supporting tumor-derived 
tissue factor (TF) 60, 61, 62, factor X (FX)-activating cysteine proteinases 60, 63, and platelet-
activating mucins 60, 64, among others 60, as potential mechanisms of cancer 
procoagulation. 
 
In addition to cancer causing thrombosis, the corollary is also true: procoagulant status 
enhances tumor metastasis.  Incubating cancer cells with soluble fibrin 65 or thrombin 66, 67 
prior to injection into murine models enhance their metastatic potential, and mice with 
the procoagulant factor V (FV) Leiden variant have more metastases. 68  It logically 
follows, therefore, that metastasis can be reduced by downregulation, deficiency and 
inhibition of various coagulation pathway players—from factors like  
TF 69, 70, 71, 72, 73, 74, prothrombin 69, 75 and fibrinogen 69, 75, 76, 77 to receptors such as  
PARs 69, 77, 78 and P-selectin 69, 79, 80, 81 to even platelets 69, 82, 81, 77.  Likewise, hemophiliac 
mice develop fewer metastatic lesions compared to wild type mice 68. 
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The exact mechanisms through which the coagulation cascade contributes to metastatic 
disease are debated, but there are data supporting a number of hypotheses, suggesting it is 
multi-faceted.  Clots facilitate cancer cell spreading and endothelial adhesion 69, 83, 
partially by giving the cancer cells a surface to adhere to and partially by slowing down 
the flow of blood and protecting against shear stress 84, 69.  Platelet and endothelial PARs 
and P-selectins 69, 81 might provide necessary extravasation receptors, and recruited 
platelets 69, 85, monocytes and macrophages 69, 86 can promote tumor cell growth and 
survival.  Protecting the nascent tumors from destruction by the immune system is 
equally important; clots can physically block natural killer (NK) cells from accessing 
tumor cells for lysis and induce NK quiescence. 69, 87, 88, 82, 75, 89, 90 
 
With such overwhelming evidence that coagulation enhances cancer progression, 
therapies targeting the coagulation cascade have been explored for their ability to prevent 
cancer progression in animal models.  Coumadin (warfarin) reduced the number of lung 
tumors formed in rats injected intravenously with cancer cells 69, 91, as did hirudin in  
mice 69, 92, 93.  Anticoagulants have also tentatively proven to be beneficial in cancer 
patients.  Low molecular weight heparin has been shown to confer a survival benefit to 
cancer patients 94, 95, although not consistently 96, and the role of warfarin in preventing 
tumor formation or metastasis is humans is debatable.  Daily aspirin reduced disease 
progression 97 and death 98 in patients with prostate cancer, breast cancer 99, and other 
cancers 100, and reduced the frequency of disease recurrence in patients with colorectal 
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cancers 101, 102.  Of course, aspirin has multiple effects beyond just anti-coagulation, 
including reducing inflammation, which may be at least partially responsible for the 
reduced risk of cancer progression. 
 
Activated protein C (aPC)—the focus of Chapters 4 and 5—is another anti-coagulant that 
has been shown to have protective effects in animal models of cancer 103, 104.  aPC is a 
vitamin-K dependent, serine protease glycoprotein that circulates in plasma as a zymogen 
(zyPC), i.e. an inactive enzyme precursor.  The human protein C (hPC) PROC gene is 
found on chromosome 2 and encodes the 419 amino acid proenzyme 105, which consists 
of a phospholipid-binding Gla domain, an aromatic stack segment, two epidermal growth 
factor (EGF)-like domains, an activation peptide, and a protease domain 106.  Most zyPC 
circulates as a heterodimer consisting of a heavy chain (the activation peptide and the 
protease domain) and a light chain (the Gla domain, aromatic stack, and EGF-like 
domains).  Cleavage at arginine 169 in the heavy chain by thrombin releases the 
activation peptide, converting the zymogen to aPC.  This cleavage event requires 
thrombin to be bound to its transmembrane cofactor, thrombomodulin (TM), on the 
endothelium and is kinetically disfavored unless zyPC is bound to its endothelial protein 
C receptor (EPCR) 106. 
 
EPCR (CD201) is a non-signaling transmembrane protein with homology to the 
CD1/major histocompatibility complex superfamily 107, 106 expressed on the surface of 
endothelial cells 106, 107, 108 as well as NK cells, monocytes, neutrophils and eosinophils.  
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Expression on the endothelium is uneven, with higher levels found on the surface of 
larger vessels 109, 110.   EPCR is bound by zyPC and aPC with equal affinity 111, 112 at a KD 
that indicates, based on hPC circulating plasma levels, that the majority of EPCR should 
be occupied by PC 113.  This makes PC an anticoagulant “on demand,” ready and waiting 
to be activated by thrombin.  
 
Activated protein C’s anticoagulant function is mediated through its protease domain.  
Upon activation by the thrombin-TM complex, aPC can dissociate from EPCR and 
localize to the phospholipid bilayer on cell surfaces, where aPC irreversibly cleaves 
activated factors V and VIII (FVa and FVIIIa), leading to their inactivation 114.  It is 
worth noting that FVIIIa is inherently unstable, and whether physiologic levels of aPC 
will actually cleave FVIIIa prior to spontaneous inactivation via dissociation of the A2 
domain is debated 106.   Cleavage of FVa is greatly enhanced by PC’s non-enzymatic 
cofactor, protein S, while cleavage of FVIIIa is only moderately improved 106, 115. 
 
Activated protein C also has anti-inflammatory and cytoprotective effects on the 
endothelium affected by EPCR and the G-protein coupled receptor PAR-1 (protease-
activated receptor 1).  PAR-1 signaling is initiated when an extracellular N-terminal 
cleavage event produces a new N-terminus, which acts as a tethered ligand and results in 
outside-in signaling 109, 116.  Notably, this signaling can result either in the aPC-mediated 
anti-inflammatory and cytoprotective effects or in thrombin-mediated pro-inflammatory 
and barrier disruptive effects depending on the context in which the cleavage occurs.  
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There is contention in the field as to whether the cytoprotective cleavage is directly by 
aPC (upon activation, a large portion—at least 30%—of aPC remains bound to  
EPCR 113, 117), which can perhaps cleave PAR-1 at a unique site and thus produce a novel 
tethered ligand responsible for the differential signaling 118.  Alternatively, disruption of 
receptor clustering in caveolae of PAR-1 with EPCR due to aPC-EPCR binding might 
lead to cytoprotective Gi signaling even with normal thrombin cleavage 113.  Interestingly, 
there is some indication that occupation of EPCR by either aPC or zyPC is equally able to 
induce these cytoprotective responses 113, 119, which given majority occupation of EPCR 
with PC suggests the default pathway is cytoprotective 113.   
 
Regardless of the specific mechanism, in this context, aPC and/or thrombin cleavage of 
PAR-1 on the endothelium leads to Gi intracellular signaling that can alter gene 
expression in endothelial cells, resulting in anti-inflammatory activities, protection from 
apoptosis, and tightening of the endothelial cell-cell junctions. 109  Modulation of gene 
expression includes inducing expression of various anti-inflammatory cytokines and 
receptors while downregulating nuclear transcription factor κB (NFκB) and thus various 
adhesion molecules, inflammatory cytokines, and apoptotic factors 109, 120, 121, 122, 123, 124.  
Additionally, PAR-1 signaling pathway results in downstream activation of sphingosine 
kinase-1 (SphK-1) followed by formation of sphingosine-1-phosphate (S1P) and 
signaling through the S1P receptor-1 (S1P1), 109, 125 which mediates aPC’s barrier 
protective effects by stabilizing the endothelial cell cytoskeleton and reducing vascular 
permeability 109, 126, 127. 
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With two distinct activities of aPC, the question then becomes how is aPC controlling 
cancer progression?  With the extensive evidence that coagulation enhances metastasis 
and anti-coagulants inhibit tumor formation, there seems to be a place for the anti-
coagulative properties of aPC in cancer modulation.  However, a study utilizing anti-aPC 
antibodies demonstrated that knocking out aPC function completely—i.e. both the 
cytoprotective and anti-coagulation effects—enhances tumor formation in a model of 
metastasis, but just blocking anti-coagulation while leaving cytoprotection intact does 
not.  Furthermore, stimulating S1P1 with an agonist can reverse the enhanced metastasis 
caused by the complete anti-aPC blocking antibody. 103  Together, these findings suggest 
that endogenous aPC limits tumor metastasis through aPC’s cytoprotective activities via 
PAR-1 and downstream S1P1 signaling.  An additional study has also shown that 
overexpression of EPCR in transgenic mice resulted in reduced tumor formation in the 
same murine model of metastasis, 104 implicating involvement of EPCR.  While 
compelling, these studies do not resolve whether exogenous aPC-mediated protection 
works through the same cytoprotective mechanism or how, exactly, EPCR is involved. 
 
IV. Dissertation goals 
The goals of this dissertation are two-fold: 
(1) While tolerization to the transgene following AAV-based expression in the liver has 
been shown to induce tolerance and prevent inhibitor formation in canine and murine 
models of hemophilia, the ability of such gene therapy to reverse an ongoing immune 
 
16 
 
response in an outbred, large-animal model is yet unknown.  In Chapters 2 and 3, I 
investigate the ability of liver-directed, AAV gene therapy to eradicate anti-factor, 
inhibitor-based immune responses in outbred, large-animal canine models of hemophilia 
A and B, and I begin to explore the possible mechanisms through which this immune 
modulation takes place.  Chapter 2 focuses on hemophilia A and attempts to characterize 
the induced CD4+ CD25+FoxP3+ T cell (potential Treg) response.  Chapter 3 concentrates 
on hemophilia B and the cytokine profile of a dog undergoing inhibitor eradication 
following gene therapy.  I hypothesized that AAV mediated liver expression would 
successfully eradicate anti-FVIII and anti-FIX inhibitors in outbred hemophilia A and B 
dogs through a mechanism involving induced Tregs. 
 
(2) Activated protein C has been shown to have anti-metastatic effects, with published 
data suggesting the endogenous aPC’s cytoprotective effect mediated through the PAR-
1/S1P1 intracellular signaling pathway is primarily responsible, with integral involvement 
of EPCR.  Additionally, there is widespread support for the idea that modulation of the 
clotting cascade can also have a negative effect on tumor progression, indicating that 
perhaps aPC’s anticoagulation functions could be involved in the ability of high doses of 
recombinant aPC to greatly reduce the number of metastases seen in a murine model of 
metastatic melanoma.  In Chapter 4 I thoroughly examine the necessity and sufficiency of 
aPC’s anticoagulant properties and cytoprotective effects in its ability to protect against 
tumor metastasis.  In Chapter 5 I further examine the possible mechanism(s) of action of 
aPC- and zyPC-mediated protection against metastasis, focusing on EPCR and other 
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previously identified putative white blood cell and platelet receptors 113.  I hypothesized 
that aPC and zyPC work through a common, novel mechanism, independent of both the 
anti-coagulative and cytoprotective effects of the protein C pathway. 
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CHAPTER 2 
ERADICATION OF NEUTRALIZING ANTIBODIES TO FACTOR VIII IN CANINE 
HEMOPHILIA A FOLLOWING LIVER GENE THERAPY* 
 
 
I. Introduction 
Hemophilia A (HA) is an X-linked bleeding disorder characterized by deficiency in the 
activity of factor VIII (FVIII), a key component of the coagulation cascade.  The disease 
occurs in approximately 1 in 10,000 live births worldwide, and >40% of these patients 
have severe disease, characterized by factor VIII activity <1% of normal. 128  Intravenous 
infusion of plasma-derived or recombinant FVIII is the standard treatment.  Antibodies 
that neutralize the protein replacement therapy (clinically termed “inhibitors”) develop in 
20-30% of young, severe and moderate HA patients, resulting in high morbidity and 
mortality 129, 130, and are also a growing problem for adults. 131, 132  Risk factors for 
inhibitor formation include both genetic and environmental factors.  The underlying 
mutation in the FVIII gene such as large gene deletions, nonsense mutations, and the 
most common mutation in severe HA patients—the inversion of intron 22—are all 
associated with inhibitor formation.  However, it is not possible to predict with certainty 
which patients will develop inhibitors, and thus, preventive strategies are not currently 
feasible. 133, 134, 135  Patients with high titers of inhibitors, defined as >5 Bethesda Units 
                                                 
*Most text and figures taken or modified from Finn JD, Ozelo MC, Sabatino DE, Franck HWG, Merricks 
EP, Crudele JM, Zhou S, Kazazian HH, Lillicrap D, Nichols TC, Arruda VR. Eradication of neutralizing 
antibodies to factor VIII in canine hemophilia A following liver gene therapy. Blood. 2010;116(26):5842-
5848. 
 
19 
 
(BU) cannot usually be treated with FVIII replacement, necessitating the use of 
extremely expensive products that bypass the procoagulant effect of FVIII. 128  Thus, 
strategies for eradication of inhibitors are of fundamental clinical relevance. 
 
Currently, the only proven therapy for inhibitor eradication is based on antigen-specific 
immune tolerance induction (ITI) protocols that stem from observations in the 1970’s that 
continuous administration of large amounts of FVIII protein could lead to a reduction in 
inhibitor titers. 136  Current ITI involves daily infusions of FVIII protein for an average of 
33 months to achieve complete eradication and is commonly followed by long-term 
prophylaxis.  This imposes enormous challenges for pediatric patients that often require 
central venous catheters that are associated with a high risk of infection and thrombosis.  
In addition, the economic burden of this strategy is remarkable (~US$1 million) and 
prohibitive for many patients outside the developed world. 129 
 
Adeno-associated viral (AAV) vectors are one of the most extensively studied and highly 
used vector platforms for gene therapy applications.  The safety profile of AAV vectors 
in clinical studies enrolling adult and pediatric populations has been excellent. 137, 138, 139, 
140  The first clinical studies using AAV to deliver the factor IX gene to the muscle or 
liver in subjects with hemophilia B were safe, without sustained toxicity. 137, 141, 142  The 
therapeutic doses defined in canine hemophilia B models were excellent predictors of the 
efficacy observed in clinical trials. 143, 144  Thus, the use of large animal models has been 
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essential for the successful translation of gene therapy protocols from the bench to the 
clinic. 145 
Liver-directed gene expression by AAV vectors has been associated with antigen-specific 
immune tolerance induction in naïve adult large animals, including severe HA dogs. 144, 
145, 146, 147, 148, 149, 150  More difficult than preventing an immune response is the challenge 
of reversing an ongoing immune response to FVIII.  We hypothesize that continuous 
expression of FVIII following AAV liver gene transfer could mimic ITI protocols with 
the additional advantage that after inhibitor eradication, the continuous expression of 
FVIII above 1% of normal would convert the disease phenotype from severe to moderate 
or mild. 
 
II. Materials and Methods 
AAV vector production 
Recombinant AAV vectors were produced by a triple transfection protocol as previously 
described, 137  using plasmids expressing canine FVIII (cFVIII) light chain (LC) or heavy 
chain (HC) in separate vectors under the control of a liver-specific promoter (human 
thyroxine binding globulin, TBG) 147 or expressing cFVIII B-domain deleted (BDD) in a 
single vector under the control of a liver-specific promoter/enhancer (human alpha 1 
antitrypsin, hAAT), a second plasmid supplying adenovirus helper functions, and a third 
plasmid containing the AAV-2 rep gene and the AAV-8 cap gene.  Vectors were purified 
by repeated cesium chloride density gradient centrifugation.  Vectors were generated in 
the Children's Hospital of Philadelphia Research Vector Core. 
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Animal procedures 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee at the Children's Hospital of Philadelphia, the University of North Carolina 
(UNC) at Chapel Hill, and Queen’s University.  Four adult male HA dogs with pre-
existing anti-FVIII inhibitors were administered 2.5 x 1013 vg/kg of AAV8-cFVIII-LC 
and 2.5 x 1013 vg/kg AAV8-cFVIII-HC intravenously via the saphenous vein in a total 
volume of 10 mL/kg PBS (K01, K03, L44, and Wembley).  Pooled normal plasma was 
concurrently given for cFVIII replacement to dog K03 to control an ongoing bleeding 
episode from a previous jugular vein puncture the day prior to vector delivery.   
 
Control animals for Treg responses: One HA dog without pre-exiting inhibitors was 
administered 6.0 × 1012 vg/kg of AAV8-cFVIII-HC and AAV8-cFVIII-LC (Linus), one 
was administered 4 × 1013 vg/kg AAV8-HCR-hAAT-cFVIII-BDD (M06), and one was 
administered 2 × 1013 vg/kg of AAV8-HCR-hAAT-cFVIII-BDD (L51), all by peripheral 
venous injection.   
 
Systemic and local toxicology 
Hematologic and comprehensive biochemical analyses of blood and serum samples for 
liver and kidney function tests were performed as previously described. 146, 150 
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Canine FVIII antigen, activity and antibody assays 
The whole blood clotting time (WBCT) was determined as previously described. 151  
Pooled normal canine plasma was used as a standard for the quantitation of the activity 
by Chromogenix Coatest SP4 FVIII (Diapharma, Lexington, MA). cFVIII-LC antigen 
levels were analyzed by enzyme-linked immunosorbent serologic assay (ELISA) using a 
monoclonal antibody against cFVIII-LC (2C4.1C3) as capture antibody as previously 
described. 151 Anti-cFVIII antibodies were detected by Bethesda assay or as cFVIII-
specific IgG antibodies by ELISA as previously described. 151  It should be noted that the 
detection of inhibitor titers less than 1 BU is unreliable in the canine HA system. 
 
Flow cytometry 
Anti-canine CD25 antibody (P4A10) was generously provided by V.K. Abrams (Seattle, 
WA) 152 and was conjugated to AlexaFluor 488 using a commercially available kit 
(Invitrogen, Carlsbad, CA).  Subsequently, P4A10-eFluor 660 was purchased from 
eBioscience (San Diego, CA). Peripheral blood mononuclear cells (PBMCs) from K01, 
K03 and L44 were surface stained for canine CD4-RPE (AbD Serotech, Raleigh, NC) 
and CD25-AF488 (P4A10) and intracellular stained with a cross reactive mouse FoxP3 –
APC (eBioscience, San Diego, CA). PBMCs from L51, Linus, and M06 were surface 
stained for canine CD3-FITC (AbD Serotech), CD4-RPE (AbD Serotech), and CD25-
eFluor660 (eBioscience) and intracellular stained for mouse FoxP3 –PerCP-Cy5.5 
(eBioscience). Samples were run on a BD Canto flow cytometer and data was analyzed 
using FlowJo software (Treestar, Ashland, OR). 
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Protein infusion for immunologic challenges and pharmacokinetic analysis 
Recombinant B-domain deleted canine FVIII (rBDD-cFVIII) purified protein was 
infused intravenously (100 IU/kg) for pharmacokinetics assessment and blood was 
collected at time points indicated.   Canine FVIII levels were determined by ELISA and 
the half-life was calculated as previously described. 151  Immunologic challenges were 
carried out by infusion of 25 IU/kg/dose body weight of rBDD-cFVIII on a weekly basis 
(total 4 doses). Pooled normal dog plasma was infused at 25 ml/dose in a similar fashion. 
 
III. Results 
Pre-existing inhibitor dogs 
We used two strains of severe HA dogs prone to inhibitor formation to test our 
hypothesis that continuous expression of FVIII could eradicate inhibitors. These dogs 
have circulating FVIII antigen and activity levels <1% of normal and faithfully reproduce 
many of the symptoms and phenotype of severe hemophilia in humans. Moreover, the 
causative mutation in both canine models 153, 154 mimics the intron 22 inversion observed 
in ~40% of severe disease in humans. 155 The first strain is from a subset of the UNC-
Chapel Hill colony that developed anti-cFVIII inhibitory antibodies upon exposure to 
normal canine plasma. 145 The second strain is from the Queen’s University dog colony, 
which has a high risk of inhibitor formation upon cFVIII protein replacement. 156, 157 This 
immunological phenotype makes these subsets of dogs more representative of the human 
hemophilia population, and dogs with inhibitors are ideal candidates for testing the safety 
and efficacy of AAV-mediated immune tolerance induction protocols. 
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Due to the large size of the canine F8 gene—even the fully functional B-domain deleted 
FVIII 151—and the limited packaging capacity of AAV vectors (4.7 Kb), the cFVIII 
cDNA was divided into two different AAV8 vectors expressing either the cFVIII LC or 
HC under control of a liver-specific promoter. 147 
 
Three HA dogs with inhibitors (K01, K03 and L44) from the UNC-Chapel Hill dog 
colony were administered 2.5 x 1013 vg/kg of each AAV8-cFVIII-LC and AAV8-cFVIII-
HC vector (5 x 1013 vg/kg total). The clinical characteristics of these dogs are shown in 
Table 2.1. The inhibitory antibodies identified in these dogs are restricted to the IgG2 
subclass (equivalent to IgG4 in humans, 158 the most common inhibitor subclass). 
 
To overcome the challenges of achieving hemostasis in these fragile animals, the vector 
was delivered by peripheral intravascular administration via saphenous vein. Thus, no 
exogenous recombinant cFVIII or transfusion of normal plasma was required during the 
vector infusion (except in K03, see subsequent pages). 
 
Table 2.1. Summary of inhibitor eradication in HA dogs following cFVIII 
expression by AAV vector 
Dog 
Age, 
yr 
Body 
weight, 
kg 
Inhibitors 
cFVIII 
activity 
plateau     
Bleeds per 
month 
Duration 
before 
treatment 
Historical, 
BU 
Time to 
eradication, 
wk 
Pre Post 
K01 1.7 20.1 8 mo 12 5 1.5 % 3/20 2*/80 
K03 1 19.3 7 mo 12 4 8 % 7/12 2*/85 
L44 0.7 16 4 mo 4.5 4 1.5 % 5/8 4†/75 
Wembley 4.9 16.5 ~2 yr 3.6 100 1.8 % - - 
      Total 15/40 8/235 
*One bleed associated with liver biopsy.     †One bleed associated with trauma from a dogfight. 
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Figure 2.1 cFVIII expression and anti-cFVIII antibody responses in Chapel Hill 
hemophilia A dog K01 following liver delivery of AAV-cFVIII. An HA dog (K01) 
with pre-existing inhibitors to cFVIII was administered 2.5 x 1013 vg/kg of AAV8-TBG-
cFVIII-HC and AAV8-TBG-cFVIII-LC by peripheral venous injection.  (A,B) cFVIII 
antigen levels were assayed by a cFVIII-LC specific ELISA and activity was monitored 
by Coatest.  (C) Anti-cFVIII antibody responses were measured by anti-cFVIII IgG2 
ELISA and Bethesda assay. (D) WBCT for a normal dog is shown in green (<12 
minutes), and WBCT for an HA dog is down in pink (>45 minutes).  Black arrows 
indicate 4 weekly challenges with 500 U recombinant B-domain deleted cFVIII. 
 
 
K01 had a historical maximum inhibitor titer of 12 BU and his inhibitor titer at the time 
of treatment was ~3 BU.  After vector administration we observed a rapid increase in 
cFVIII expression (Figure 2.1A), peaking at day 3 (38 ng/mL LC antigen, 1.5% activity). 
This is consistent with the pattern of early expression of AAV-8 vectors. However, 
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transgene expression levels decreased to near background levels for 3-4 weeks and then 
slowly increased over time to reach cFVIII plateau levels of 30 ng/ml LC antigen and 
1.5% activity.  Inhibitor titers followed an inverse relationship with cFVIII antigen and 
activity levels.  There was an initial decrease in inhibitor titer to undetectable levels, 
followed by rapid increase, peaking at 6 BU on day 8 and then slowly decreasing over 
time, and no longer detectable by day 42 (Figure 2.1C). During this time, we 
documented an increase in inhibitor titers corresponding to a decrease in cFVIII 
expression, indicating an anamnestic inhibitor response followed by inhibitor eradication. 
This is a common observation during the early phase of ITI. 159  K01 has been followed 
for more than four years with sustained cFVIII expression (Figure 2.1B). 
 
The kinetics of cFVIII expression in dogs L44 (2.2 BU) and K03 (3 BU) were similar to 
K01. It should be noted that K03 received a transfusion of normal canine plasma at the 
time of vector injection to control bleeding from a jugular puncture received the previous 
day when collecting baseline samples.  Thus the cFVIII antigen and activity from the 
transfusion confounds the quantification of the AAV-cFVIII mediated expression at early 
time points (days 2-3). In both dogs there was a rapid increase in the circulating cFVIII 
levels followed by a decrease to undetectable levels from 7 to 21 days (Figure 2.2A, 
2.3A).  This transient decrease in transgene expression is not observed in non-inhibitor 
hemophilia dogs administered AAV and is an indication of an anamnestic immune 
response against cFVIII. 144, 146, 149, 150  Inhibitor titers increased starting 1 week after 
treatment followed by a slow decrease with complete eradication 4-5 weeks post AAV  
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Figure 2.2 cFVIII expression and anti-cFVIII antibody responses in Chapel Hill 
hemophilia A dog L44 following liver delivery of AAV-cFVIII. An HA dog (L44) 
with pre-existing inhibitors to cFVIII was administered 2.5 x 1013 vg/kg of AAV8-TBG-
cFVIII-HC and AAV8-TBG-cFVIII-LC by peripheral venous injection.  (A,B) cFVIII 
antigen levels were assayed by a cFVIII-LC specific ELISA and activity was monitored 
by Coatest.  (C) Anti-cFVIII antibody responses were measured by anti-cFVIII IgG2 
ELISA and Bethesda assay. (D) WBCT for a normal dog is shown in green (<12 
minutes), and WBCT for an HA dog is down in pink (>45 minutes).  Black arrows 
indicate 4 weekly challenges with 500 U recombinant B-domain deleted cFVIII. 
 
 
 
 
 
delivery (Figure 2.2C, 2.3C).  L44 and K03 have been followed for more than four years 
with sustained cFVIII expression (Figure 2.2B, 2.3B). 
 
We observed an expected inverse relationship between cFVIII expression and inhibitor 
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Figure 2.3 cFVIII expression and anti-cFVIII antibody responses in Chapel Hill 
hemophilia A dog K03 following liver delivery of AAV-cFVIII. An HA dog (K03) 
with pre-existing inhibitors to cFVIII was administered 2.5 x 1013 vg/kg of AAV8-TBG-
cFVIII-HC and AAV8-TBG-cFVIII-LC by peripheral venous injection.  (A,B) cFVIII 
antigen levels were assayed by a cFVIII-LC specific ELISA and activity was monitored 
by Coatest.  (C) Anti-cFVIII antibody responses were measured by anti-cFVIII IgG2 
ELISA and Bethesda assay. (D) WBCT for a normal dog is shown in green (<12 
minutes), and WBCT for an HA dog is down in pink (>45 minutes).  Black arrows 
indicate 4 weekly challenges with 500 U recombinant B-domain deleted cFVIII (starting 
day 140) and 4 weekly challenges with 25 ml of pooled normal canine plasma (starting 
day 400). 
 
 
titers, with cFVIII levels steadily increasing as inhibitor titers decreased to undetectable 
levels. cFVIII levels stabilized at 1-2% (for dogs L44 and K01) and 8% for K03. The 
reasons for this discrepancy in cFVIII expression levels are unclear; however, we 
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previously showed that normal hemostasis at the time of AAV2 vector delivery enhances 
transgene expression in murine models. 160 Thus, it is possible that correction of 
hemostasis by normal plasma infusion in K03 may have contributed to the higher 
efficiency of gene transfer. 
 
A consequence of using a dual-chain approach is an imbalance in circulating cFVIII LC 
and HC antigen levels, with the LC antigen being secreted 10-25 times more efficiently 
than the HC. 161, 162 A large proportion of cells are presumably transduced with only one 
of the vectors, and these cells will produce cFVIII antigen that is inactive without its 
complementary chain. Thus, cFVIII antigen levels are higher than the cFVIII activity 
levels (~10 fold). We speculate that this excess of antigen is perhaps beneficial in 
inducing immune tolerance by increasing the overall amount of circulating antigen, as 
shown before in murine models. 163 The cFVIII activity observed in these dogs reached 
therapeutic levels as demonstrated by a sustained shortening of the whole blood clotting 
time (Figure 2.1D, 2.2D, 2.3D) in all three dogs and a remarkable improvement of the 
disease phenotype with reduction of more than 90% of bleeding episodes (Table 2.1). 
 
In order to determine whether these animals were tolerant to cFVIII, we performed 
immunological challenges with purified recombinant B domain-deleted cFVIII (rBDD-
cFVIII). 151  K01, K03, and L44 were challenged with 4 weekly intravenous injections of 
25 IU/kg body weight (2.5 µg/kg) of rBDD-cFVIII initiated on various days post vector  
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Figure 2.4 Recovery of cFVIII 
following intravenous administration. 
Recombinant B-domain deleted (rBDD) 
cFVIII was administered (100 IU/kg) to 
K01 and K03 by intravenous injection 
and cFVIII activity was monitored over 
time by Coatest assay. 
 
 
administration (day 240, 140, and 113 respectively) and monitored for inhibitor 
formation.  As can be seen in Figures 2.1-2.3, there was no change in cFVIII expression 
levels or indication of either inhibitor formation or non-neutralizing antibodies after 
challenge in any dog.  In order to confirm that tolerance induction is sustained upon 
exposure to the wild type (full-length) cFVIII, we further challenged K03 starting on day 
400 with 4 weekly injections of 25 ml of pooled normal canine plasma per dose. Once 
again, no evidence of inhibitors or antibodies to cFVIII was observed (Figure 2.3). 
 
In order to further confirm the eradication of inhibitors and exclude the presence of non-
neutralizing antibodies that might increase the clearance of cFVIII, we determined the 
recovery and half-life of cFVIII protein in K01 and K03.  Both dogs were infused with 
100 IU/kg of rBDD-cFVIII and plasma was collected 5 minutes to 48 hours post-
infusion.  As can be seen in Figure 2.4, there was an excellent recovery of more than 
80% of the infused protein measured at 5-10 min post injection. We determined similar 
cFVIII fall-off curves, with a terminal half-life of ~14hrs in both dogs. These findings are 
comparable to our previously reported data on pharmacokinetic parameters obtain in 
naïve HA dogs. 151 
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As previous data using liver directed gene transfer to prevent immune responses in 
animal models has shown the involvement of regulatory T cells, 164, 165, 166, 167 we used 
flow cytometry to determine the frequency of CD4+CD25+FoxP3+ T cells at baseline and 
various subsequent time points over the first 150 days after vector administration.  
Interestingly, we observe an increase in CD4+CD25+FoxP3+ T cells at weeks 1 and 2, 
with a return to baseline levels by week 4 (Figure 2.5A, Table 2.2).   When the 
CD4+CD25+FoxP3+ T cell kinetics of these dogs were compared with two non-inhibitor 
HA dogs (M06 and Linus) from UNC treated with the same or similar AAV vectors, the 
same expansion was not seen (Figure 2.5A).  M06 and Linus had never had nor ever 
developed inhibitors.  Conversely, L51 was an HA dog from UNC’s inhibitor-prone sub-
colony with no history of inhibitors upon AAV administration that developed a transient 
inhibitor after treatment (Figure 2.5B).  The frequency of L51’s CD4+CD25+ FoxP3+ T 
cells plummeted during inhibitor onset, but then rose concurrently with the eventual 
induction of FVIII tolerance.  The kinetics of CD4+CD25+FoxP3+ T cell frequencies in 
these dogs suggests that the expansion of CD4+CD25+FoxP3+ T cells seen in K01, K03 
and L44 is not simply a response to the influx of AAV vector or onset of FVIII 
expression.  Rather, the data is suggestive of an expansion of tolerance-inducing Tregs as 
has been seen in previous AAV liver-directed murine and non-human primate studies. 164, 
165, 166  While further studies are required to determine the exact mechanism of tolerance 
induction in this model, our data is consistent with the hypothesis that regulatory T cells 
might be, at least in part, involved in this phenomenon.  
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Figure 2.5 Frequency of CD4+CD25+FoxP3+ T cells following liver delivery of AAV-
cFVIII in Chapel Hill hemophilia A dogs with and without inhibitors. (A) HA dogs 
with pre-existing inhibitors to cFVIII (K01, K03, L44) were administered 2.5 x 1013 
vg/kg of AAV8-TBG-cFVIII-HC and AAV8-TBG-cFVIII-LC by peripheral venous 
injection.  HA dogs without pre-exiting inhibitors were administered 6.0 × 1012 vg/kg of 
AAV8-TBG-cFVIII-HC and AAV8-TBG-cFVIII-LC (Linus) or 4 × 1013 vg/kg AAV8-
HCR-hAAT-cFVIII-BDD (M06) by peripheral venous injection.  PBMCs collected 
before and periodically after AAV administration were collected and stained for CD3, 
CD4, CD25, and FoxP3 and analyzed by flow cytometry.  Cells were gated by size on the 
lymphocyte population and the frequency of CD25+FoxP3+ cells in the CD3+CD4+ T cell 
population was quantitated and normalized to baseline.  (B) An HA dog (L51) from the 
inhibitor prone population that had no pre-existing inhibitor to cFVIII was administered 2 
× 1013 vg/kg of AAV8-HCR-hAAT-cFVIII-BDD by peripheral venous injection.  
PBMCs were collected before and periodically after AAV administration and stained and 
analyzed as described in A (red line).  cFVIII antigen levels (blue line) were assayed by a 
cFVIII-LC specific ELISA and anti-cFVIII antibody responses (black line) were 
measured by anti-cFVIII IgG2 ELISA. 
 
 
 
 
 
 
Table 2.2 Flow cytometry analysis of total PBMC’s from Chapel Hill inhibitor dogs 
Dog 
% CD25+FoxP3+ of total CD4+ T cells (SD*) 
Baseline (d0) Peak (w1-2) Plateau (w12) 
K01 1.05 (0.09) 2.61 (0.30) 0.94 (0.06) 
K03 2.45 (0.05) 4.60 (0.26) 2.58 (0.03) 
L44 1.01 (0.10) 1.50 (0.11) 1.16 (0.10) 
*SD = standard deviation of triplicate analysis of sample 
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Next we treated a dog (Wembley) from the colony at Queen’s University 168. Wembley 
developed inhibitors after primary exposure to recombinant human FVIII, and these 
inhibitory antibodies were found to cross-react with canine FVIII. He received further 
infusions of cryoprecipitate containing large amounts of canine FVIII.  At the time of 
vector injection, the inhibitor titers against cFVIII were 3.5 BU.  After administration of 
AAV8-cFVIII vector we observed a rapid increase in cFVIII antigen and activity 
reaching levels of 74 ng/ml and 10%, respectively (Figure 2.6A). These levels quickly 
decreased to pretreatment levels coinciding with a remarkable increase in inhibitor titers 
and anti-cFVIII IgG2 (Figure 2.6B).  A similar finding was observed for anti-cFVIII 
IgG1 (data not shown).  His inhibitors showed a strong anamnestic response, with 
Bethesda titers peaking at 216 BU on day 21 (Figure 2.6B). We continued to monitor the 
levels of cFVIII and anti-cFVIII antibodies. Over the following two years the anti-cFVIII 
inhibitor titers gradually decreased undetectable levels.  As the inhibitor titers decreased, 
we began to observe a rise in cFVIII LC antigen and activity levels, to 28 ng/mL and 
1.8%, respectively (Figure 2.6A).  Wembley is now 74 months out from vector 
administration, with stable cFVIII expression levels for 26 months.  He was recently 
challenged with rBDD-cFVIII and will be monitored for any potential return of 
inhibitors.  This dog resembles to a certain extent the kinetics of high responder patients 
with substantial increase in the inhibitor levels upon exposure to FVIII protein. 159 In the 
high responder patients, ITI failure rates increase to more than double that of non-high 
responders. 129  Moreover, anamnestic response with BU > 200 IU is also associated with 
poor response to ITI.  Interestingly, Wembley’s anti-human FVIII inhibitors rose from a   
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Figure 2.6 cFVIII expression and anti-cFVIII antibody responses in Queen’s 
University high-responding inhibitor hemophilia A dog Wembley following liver 
delivery of AAV-cFVIII. An HA dog (Wembley) with pre-existing inhibitors to hFVIII 
and cFVIII was administered 2.5 x 1013 vg/kg of AAV8-TBG-cFVIII-HC and AAV8-
TBG-cFVIII-LC by peripheral venous injection.  (A) cFVIII antigen levels were assayed 
by a cFVIII-LC specific ELISA and activity was monitored by Coatest.  (B) Anti-cFVIII 
antibody responses were measured by anti-cFVIII IgG2 ELISA and Bethesda assay. (C) 
Anti-hFVIII antibody responses were measured by anti-hFVIII IgG2 ELISA and 
Bethesda assay. 
 
 
 
baseline value of 7.4 BU to a peak of 271 BU at d14 and have stabilized at 2.2 BU 
(Figure 2.6C).  A similar pattern was observed for the anti-hFVIII IgG2 levels, with 
current levels ~20 µg/ml.  We speculate that this indicates Wembley was tolerized to  
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Figure 2.7 Anti-AAV8 
capsid humoral responses. 
Anti-AAV8 capsid IgG2 
responses were assayed in all 
four dogs.  Plasma samples 
were assayed for capsid 
specific IgG2 by ELISA with 
plates coated with empty 
AAV8 capsid. 
 
 
specific epitopes shared between human and canine FVIII; however, there continue to be 
inhibitors specific for epitopes unique to hFVIII.  In order to confirm that the immune 
tolerance to cFVIII was specific, we measured anti-AAV8 IgG2 antibody levels.   As 
seen in Figure 2.7, all animals developed a robust and sustained anti-capsid immune 
response, indicating that these animals are fully capable of generating and maintaining 
humoral immune responses to other antigens following vector administration. 
 
IV. Discussion 
The contrast in the immunological profile and response following AAV mediated 
expression of cFVIII between the three Chapel Hill dogs and the dog from the Queen’s 
University colony is remarkable. Despite the fact that these dogs have a similar 
underlying causative mutation, all three Chapel Hill dogs (K01, K03, L44) showed mild 
anamnestic responses and rapid eradication of inhibitors in 4-5 weeks, while Wembley 
had a very strong immune response that took over a year and a half for inhibitor titers to 
decrease to background levels. There are several factors that may explain these distinct 
outcomes, including the previous exposure to xenoantigen (human FVIII) that could 
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hamper the ability to induce antigen-specific immune tolerance.  Second, there are the 
differences in strains of dogs that may reflect inherited factors similar to ethnicity as a 
genetic risk factor in humans. 134 135  Lastly, the long duration (~2 years) between 
inhibitor development and AAV administration may also influence the rates of success as 
observed in humans on ITI. 129 
 
Collectively, the data presented here demonstrate for the first time the potential of liver-
directed, AAV-mediated gene expression to induce tolerance to the transgene in the 
setting of pre-existing inhibitory antibodies in an adult, large-animal model of disease. 
The sustained expression of cFVIII from the transgene after inhibitor eradication 
recapitulates secondary prophylactic replacement protocols required to maintain immune 
tolerance in patients post successful inhibitor eradication. 129 In this model, we observed 
both inhibitor eradication and complete normalization of pharmacokinetics of FVIII 
protein infusion as well as improved disease phenotype. Overall, vector administration 
was well tolerated with no abnormalities on serial determinations of hematologic and 
biochemical analyses of blood and serum samples for liver and kidney function tests. 
 
The underlying mechanism of the success of ITI in humans is still unclear, but it has been 
investigated in preclinical studies and revealed to depend on both B and T cell response. 
169, 170 The exact mechanism of the immune tolerance induction in this HA dog study is 
currently unknown. Previous work in murine and non-human primate models has shown 
that sustained AAV-mediated expression of transgenes can induce tolerance, and that this 
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sustained expression is dependent on regulatory T cells. 164, 165, 166 In addition, recent 
work using microRNA to restrict transgene expression from a lentiviral vector to 
hepatocytes has also shown sustained transgene expression and the induction of antigen-
specific T regulatory cells. 167  While our observation that CD4+CD25+FoxP3+ T cells are 
transiently up-regulated following gene transfer is consistent with the hypothesis that 
regulatory T cells are involved, much work still needs to be done—including testing the 
function and antigen specificity of these cells—to fully investigate the mechanism of 
immune tolerance induction in this model. It is also likely that this immune tolerance 
induction involves multiple mechanisms including anergy and/or deletion. This is an area 
of research currently under investigation. 
 
Our group and others have previously demonstrated that using viral vectors to direct gene 
transfer to the liver of adult 144, 146, 148, 150 or neonatal 171, 172 large animal models can 
induce tolerance to the expressed transgene and prevent immune responses. Data on 
tolerance induction by gene therapy and/or immune modulatory strategies in the pre-
existing immune responses has been limited to murine models. 173, 174, 175 Considering the 
limited numbers of HA dogs in this study and the modest inhibitor titers at the time of 
vector administration, these findings have to be considered a proof-of-principle that 
immune tolerance induction is feasible in the setting of pre-existing immunity in a large 
animal model for an unmet medical need. These data may have relevance not only for 
hemophilia but also for a variety of diseases whereby antibody formation to the 
therapeutic protein or enzymes could prevent optimal clinical responses. 176, 177  
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CHAPTER 3 
AAV LIVER EXPRESSION OF FIX-PADUA RESULTS IN FIX INHIBITOR 
PREVENTION AND ERADICATION IN HEMOPHILIA B DOGS AND MICE† 
 
 
I. Introduction 
Hemophilia B (HB) is an X-linked inherited bleeding disease characterized by deficiency 
of factor IX (FIX) due to F9 gene mutations. Patients with severe HB (residual FIX 
activity <1% normal) have recurrent bleeding episodes associated with increase 
morbidity and mortality compared to those with moderate (FIX 1-5%) or mild disease 
(FIX >5-30%). Treatment of HB is based on protein replacement therapy, and 
prophylactic therapy is associated with clinically beneficial outcomes. One of the main 
complications of protein replacement therapy is the development of antibodies (clinically 
termed inhibitors) to the infused protein, which occurs in 1-3% of HB patients. 178, 179, 180  
Most of these patients have severe disease, and one of the main determinants of inhibitor 
formation is the underlying F9 mutation. HB patients with mutations such as missense 
mutations that lead to circulating but defective FIX antigen, termed cross reacting 
material (CRM)-positive, exhibit a lower risk of inhibitor formation compared to CRM-
negative patients. 178, 179, 181  . In contrast, approximately 50% of patients with large gene 
deletions or rearrangements develop FIX inhibitors, followed by patients with premature 
                                                 
†Most text and figures taken or modified from Crudele JM, Finn JD, Siner JI, Martin NB, Niemeyer GP, 
Zhou S, Mingozzi F, High KA, Lothrop Jr CD, Arruda VR. AAV liver expression of FIX-Padua results in 
FIX inhibitor prevention and eradication in hemophilia B dogs and mice. Submitted to Blood. 
 
39 
 
stop codon, frame shift or splice-site mutations (20-30%). 181  Thus, null mutations in F9 
significantly increase the risk of inhibitor formation. 
 
Several treatment strategies for hemophilia based on protein, nucleic acid or cell 
therapies are under development aimed at increasing factor levels to the range of 
moderate or mild disease. 182, 183, 184, 185, 186, 187  Gene therapy using adeno-associated viral 
(AAV) vectors for liver FIX gene transfer is emerging as a successful strategy as long-
term expression of circulating FIX and improvement of disease phenotype have been 
reported. 183, 188  Data from early-phase AAV-FIX clinical trials demonstrate that immune 
responses to vector capsid proteins is a main safety concern and is directly correlated to 
vector dose. 183, 188  Thus, strategies to reduce the vector dose are highly attractive to 
overcome these safety concerns. 
 
We previously reported a case of thrombophilia associated with an arginine 338 to 
leucine (FIX-R338L, FIX-Padua) substitution in F9. The mutant FIX circulates at normal 
antigenic levels but exhibits 8-fold increased clotting activity (776% of normal in the 
proband). 189  Thus, the use of FIX-Padua offers an alternative strategy for treating HB. 
Preclinical studies in severe HB dogs provide a unique opportunity to address both 
efficacy and safety of a novel strategy. There are two severe canine HB models available, 
both of which are CRM-negative.  However, the underlying F9 mutation, mRNA levels, 
and risk of inhibitor formation differ. 190, 191, 192  The University of North Carolina-Chapel 
Hill (UNC-CH) model is due to a missense mutation, glutamic acid 379 to glycine, which 
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leads to normal RNA levels but probable disruption of protein folding. 190, 191  The 
University of Alabama at Birmingham (UAB) model results from a frame shift mutation, 
premature stop codon at position 146 (null mutation) and undetectable mRNA likely due 
to transcript instability. 191  Infusion of canine FIX concentrate in naïve HB dogs resulted 
in inhibitor formation in the UAB model but not the UNC-CH model. 193, 194, 195, 196  
Preclinical studies using these models for AAV muscle gene therapy showed that the 
parameters of vector dose tested (per site, per body weight), which proved safe in the 
UNC-CH model, resulted in inhibitor formation in the UAB dogs. 193, 195, 196  Therefore, in 
the skeletal muscle-directed AAV trial only severe HB men with F9 missense mutations 
were enrolled. 197  With liver gene therapy, both canine models showed long-term 
sustained expression of FIX-WT. 193, 194, 195, 196  Thus, patients with missense and null 
mutations were enrolled in AAV liver trials. Overall, none of the 15 patients enrolled in 
these early phase studies developed FIX inhibitors. 188, 197, 198  Thus, data on immune 
responses to the transgene in these canine models are likely to be predictive of human 
responses. 
 
Here we sought to determine the immunogenicity of FIX-Padua following AAV8 liver 
gene transfer in HB dogs with a null mutation and perform comprehensive safety studies 
in mice. We hypothesized that if the expression of FIX-Padua is safe, these data will 
further enhance the potential of clinical translation of FIX-Padua to HB patients, 
including those with underlying F9 null mutations. 
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II. Materials and Methods 
Recombinant AAV vector 
Production of AAV serotype 8 vectors was carried out as previously described. 199  The 
expression cassette contained canine FIX-R338L (cFIX-Padua), human FIX-R338L 
(hFIX-Padua) or human FIX wild-type (hFIX-WT) behind a liver-specific promoter. 199 
 
Canine studies 
The Institutional Animal Care and Use Committee at the Children’s Hospital of 
Philadelphia and the UAB approved all experiments.  Three adult male HB dogs received 
AAV at doses of 1 x 1012 or 3 x 1012 vector genomes per kilogram body weight (vg/kg) 
via the saphenous vein diluted in PBS over a 30-minute period. 
 
Systemic and local toxicity  
Hematologic and biochemical analyses of blood and serum samples for liver and kidney 
functions and pathological activation of coagulation was monitored by D-dimer and 
thrombin-antithrombin (TAT) complexes levels as previously described. 200 
 
Canine FIX antigen, activity and antibody assays  
Whole blood clotting time (WBCT), cFIX antigen and activity, and thrombelastography 
(TEG) were assayed as previously described. 201, 202  Neutralizing antibodies to cFIX were 
determined by Bethesda assay and reported as Bethesda Units (BU), in which 1 BU 
inhibits 50% of clotting activity of FIX in normal canine plasma. Antibodies against cFIX 
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were measured by enzyme-linked immunosorbent assay (ELISA) against IgG1, IgG2 and 
total IgG (Bethyl Laboratories, Inc, Montgomery, TX) as previously described. 200 
 
Immune responses to AAV8 capsid proteins 
To detect antibody responses against AAV8 capsid proteins, plates were coated with 
AAV8 empty capsids (1 µg/ml) as previously described. 200  Coating with serially diluted 
dog reference serum with known quantities of IgG1 and IgG2 (Bethyl Laboratories, 
Montgomery, TX) served as a standard curve. 203 
 
Immunological challenges with canine FIX-WT protein concentrate 
Dogs were challenged with 0.5 mg of pooled plasma-derived, purified cFIX concentrate 
(Enzyme Research Laboratory, South Bend, IN) by intravenous injection at indicated 
time points. Plasma samples were collected at baseline and weeks 1, 2 and 4 post protein 
injection. Humoral responses to cFIX-WT were monitored using assays for inhibitory and 
non-inhibitory antibodies to cFIX as described above. 200 
 
Canine multiplex cytokine array 
Cytokines were assayed using a Milliplex canine cytokine MAG Panel kit (EMD 
Millipore, Billerica, MA) 8-plex containing mIL15-MAG, cGMCSF-MAG, cIFNG-
MAG, cIL2-MAG, cIL6-MAG, cIL10-MAG, cIL18-MAG, and cTNFA-MAG.  
Standards, quality controls and samples were assayed in duplicate.  The bead counts and 
fluorescence intensity of the beads was measured using a Luminex 100/200 analyzer.  
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Samples were measured once, and blank values were subtracted from all readings.  
Standard curves were produced and sample values determined using xPONENT software. 
 
Murine studies 
Assessing immunogenicity of hFIX-Padua 
Adult HB male mice on C57Bl/6 background (n=7-9 mice/group) were injected with 
AAV-hFIX-WT or AAV-hFIX-Padua at 4x1010 vg/kg.  Mice then received 2 µg/mouse 
of hFIX-WT or hFIX-Padua via subcutaneous injection every week for four weeks 
starting at week 10 post-vector. Ten weeks after the last protein injection, mice received 
hFIX-WT or hFIX-Padua (2 µg/mouse) in complete Freund’s adjuvant, CFA, (Sigma, St 
Louis, MO) and then in incomplete Freund’s adjuvant, IFA, (Sigma, St Louis, MO) 8 
weeks later. Control group consisted of adult naïve HB mice (n=4-5 mice/group) injected 
with hFIX-WT or hFIX-Padua protein alone in a similar fashion. We monitored FIX 
antigen levels, inhibitory antibodies and murine anti-hFIX total IgG at baseline, week 4 
post AAV injection and 4 weeks after the last of each protein challenge (protein alone, 
protein in CFA and protein in IFA). 
 
Long-term safety studies in mouse models 
Adult hemostatically normal male C57Bl/6 mice received AAV encoding hFIX-Padua or 
hFIX-WT at five vector doses ranging from 4 x 1010 to 2 x 1012 vg/kg (n=5 
mice/dose/vector) and were followed for several months. We determined hFIX 
expression levels by antigen and activity assays and TAT complex levels as previously 
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described 204 at 2, 5 and 8 months post vector injection. D-dimer levels were monitored 
only at 2 and 8 months post-vector injection due to sample volume limitation. 204  Kaplan-
Meier analysis was used to determine the survival rates; the control group (n=5) received 
1 x 1011 vg/kg AAV empty capsid. 
 
Recombinant hFIX-WT and hFIX-Padua protein production 
We used an expression system consisting of pLenti6.3 (ViralPower HiPerform 
Expression System, Invitrogen, Carlsbad, CA) by reversal transfection to generate a 
stable human embryonic kidney 293 cell line expressing hFIX-WT and hFIX-Padua. 
Protein purification consisted of ion exchange column followed by HQ-Shepharose 
(Applied Biosystems, Forster City, CA) column and eluted with a calcium gradient. 
 
III. Results 
Canine Studies 
Sustained expression of cFIX Padua in inhibitor-prone HB dogs is safe 
Two adult HB dogs (Wick and Trex) received AAV8 encoding cFIX-Padua at doses of 1 
x 1012 or 3 x 1012 vg/kg, respectively, by intravenous injection (Figure 3.1; Table 3.1).  
At both doses the resulting FIX activity levels were an average of 7-12 times higher than 
the antigen levels, and these activity levels put the dogs in the range of mild hemophilia. 
In these dogs the WBCT (Figure 3.1E,F) and the TEG (Figure 3.2; Table 3.2) 
normalized within a week following AAV delivery.  This was accompanied by a  
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Figure 3.1 cFIX expression and anti-cFIX humoral responses in HB dogs following 
liver delivery of AAV-cFIX-Padua. Two University of Alabama HB dogs with no 
previous history of inhibitors were assessed for (A,B) cFIX antigen and activity, (C,D) 
anti-cFIX IgG2 and Bethesda units, and (E,F) whole blood clotting times after AAV8-
cFIX-Padua administration.  Trex (A,C,E) received 3 x 1012 vg/kg and Wick (B,D,F) 
received 1 x1012 vg/kg.  Horizontal dashed lines, positive levels of B.U. and IgG2; 
vertical dashed lines, time of challenge with recombinant cFIX; pink bar, WBCT of 
hemophiliac dogs (>45 min); green bar, WBCT of normal dogs (<8 min).
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Table 3.1 Summary of AAV8-cFIX-Padua treatment of three adult dogs with severe HB 
      cFIX-Padua plateau levels  Bleeds per month 
Dog 
 
Age  
Body 
weight, kg  
Vector 
dose, vg/kg   
Vector dose, 
total dose  
Activity, % 
mean ± SD  
Antigen, % 
mean ± SD  
Specific 
activity  
Pre-
treatment  
Post-
treatment 
Wiley  2 yr 8 mo  10.2  3 x 1012  30.6 x 1012  241.2 ± 31.9  28.8 ± 9.3  8.6  7/32  0/30 
Trex  2 yr 8 mo  5.8  3 x 1012  17.4 x 1012  26.8 ± 5.5  3.81 ± 1.29  7.9  4/32  0/30 
Wick  11 mo  8.6  1 x 1012  8.6 x 1012  39.9 ± 5.8  3.33 ± 0.38  12  0/11  0/13 
Total                11/75  0/73 
 
 
Table 3.2 Thromboelastography clot formation values 
Dog  R, minutes  K, minutes  α, degrees  MA, mm 
Wiley  5.1  1.2  71.5  70.6 
Trex  4.4  1.5  68.2  67.8 
Wick  6.2  2.8  54.4  59.2 
WT dog  6.4  3.2  49.2  43.6 
HB dog  no clot detected in 60 min assay  n/a  0.25 
Normal canine range  1.8-8.6  1.3-5.7  36.9-74.6  42.9-67.9 
R indicates reaction time until detection of 2 mm clot; K, clot formation time from R until clot reaches 20 mm; α, angle of line tangent 
to the curve at K; and MA, maximum amplitude indicating clot strength 
Normal canine range from Bauer. 205 
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Figure 3.2 Thromboelastographs 
for HB dogs following liver 
delivery of AAV-cFIX-Padua. 
Thromboelastographs were run on 
kaolin-activated, citrated plasma 
collected two months after the 
dogs were challenged with protein. 
Una is an untreated HB dog; Clyde 
is a wild type dog. 
 
 
complete lack of bleeding episodes that further support the correction of the disease 
phenotype (Table 3.1).   
 
There was no formation of inhibitory or non-inhibitory antibodies to cFIX-Padua (Figure 
3.1C,D) throughout the cumulative long-term follow up of ~3.5 years (ongoing 
observations). We specifically assay for canine IgG2 subclass, which is associated with 
inhibitory antibody in this HB model upon FIX protein concentrate injection or gene 
therapy 199, 196, and is the equivalent of human IgG4 (the IgG subclass associated with 
inhibitory antibody 206).  We also assayed for canine IgG1 (Figure 3.3), but found none 
against cFIX-Padua in either dog. 
 
We challenged these dogs by intravenous injection of 0.5 mg cFIX-WT protein 
concentrate 11 months (Wick) or 2.3 years (Trex) after vector injection. We reported 
earlier that in this naïve HB dog strain this strategy induces the formation of inhibitory 
antibodies to cFIX-WT within a week post challenge 193.  Here, in the AAV-cFIX-Padua  
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Figure 3.3 Anti-cFIX humoral responses in HB dogs following liver delivery of 
AAV-cFIX-Padua.  In addition to the IgG2 ELISAs, the University of Alabama HB 
dogs were assessed for IgG1 anti-cFIX antibodies. Wiley, red; Trex, blue; Wick, green; 
horizontal dotted line indicates background levels of IgG1. 
 
 
expressing dogs, there was no detection of antibodies to cFIX by Bethesda assay or anti-
cFIX IgG2 ELISA (Figure 3.1C,D). Thus, expression of the cFIX-Padua variant shows 
increased specific activity as observed in humans with FIX-Padua 189 and no unwanted 
immune responses even upon challenge with cFIX-WT protein concentrates. 
 
Eradication of inhibitory antibodies to FIX by liver gene therapy using AAV-cFIX-
Padua 
The dog Wiley developed inhibitors after primary exposure to human FIX protein, and 
these inhibitory antibodies cross-reacted with cFIX. At the time of vector injection, the 
inhibitor titers against cFIX were undetectable by Bethesda assay but anti-cFIX IgG2 
levels were ~500 ng/ml. After administration of AAV-cFIX-Padua vector, we observed a  
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Figure 3.4 cFIX expression and anti-cFIX humoral responses in an HB dog with 
pre-existing anti-hFIX inhibitors after administration of AAV-cFIX-Padua. Wiley, a 
University of Alabama HB dog with a history of inhibitors against hFIX, was assessed 
for (A) cFIX antigen and activity, (B) whole blood clotting time, (C) anti-cFIX IgG2 and 
Bethesda units, and (D) anti-hFIX IgG2 and Bethesda units after administration of 3 x 
1012 vg/kg AAV8-cFIX-Padua.  Horizontal dashed lines, positive levels of B.U. and 
IgG2; vertical dashed lines, time of challenge with recombinant cFIX; pink bar, WBCT 
of hemophiliac dogs (>45 min); green bar, WBCT of normal dogs (<8 min). 
 
 
 
 
 
rapid increase in cFIX antigen and activity, which reached levels of 2% and 20% of 
normal, respectively. These levels quickly decreased to pretreatment levels, coinciding 
with an increase in inhibitor titers and anti-cFIX IgG2 (Figure 3.4, Table 3.1).  These 
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findings are consistent with the initial normalization of the WBCT by week 1 and a return 
to baseline levels at day 10 post vector injection. Wiley’s inhibitors showed an 
anamnestic response, with titers peaking at ~5 BU on day 15 (Figure 3.4C) followed by 
a spontaneous decline to complete eradication by day 28. Similarly, anti-cFIX IgG2 
levels peaked concomitant with the Bethesda titers but showed a slower decline, with 
total eradication at day 70.  At no point were anti-cFIX IgG1 antibodies detected (Figure 
3.3).  We continue to monitor the levels of cFIX antigen/activity and anti-cFIX 
antibodies, with no evidence of cFIX antibodies observed over 2.4 years.  Notably, 
Wiley's anti–human FIX inhibitors rose to 5.3 BU at day 14 and disappeared by day 20 
(Figure 3.4D).  The anti-hFIX IgG2 levels rose from a baseline of 5 μg/mL to a peak at 
day 14 of 11 μg/mL, but, although they are gradually declining, residual levels of ∼1.5 
μg/mL remain detectable. These data suggest that Wiley developed immune tolerance to 
specific epitopes shared between the human and canine FIX proteins; however, non-
inhibitory antibodies specific for epitopes unique to hFIX remain. Because of the 
potential systemic complications associated with inhibitory antibodies to FIX such as 
anaphylactic reaction and nephrotic syndrome 178, 207, we monitored Wiley by clinical and 
laboratory assays. No evidence of abnormal kidney function or urinary protein loss has 
been observed (data not shown). To finally confirm the eradication of inhibitory antibody 
to cFIX and immune tolerance induction, we challenged Wiley with 0.5 mg cFIX-WT 
protein concentrate 2.3 years after vector injection. Again, no humoral responses were 
documented by Bethesda assay or anti-cFIX IgG2 ELISA (Figure 3.4C).  Together these 
findings show that AAV liver expression of cFIX-Padua is efficacious in eradicating  
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Figure 3.5 Cytokine profiles of dogs following AAV-cFIX-Padua liver gene therapy. 
A cytokine multiplex array was run to assess the levels of (B) GM-CSF, (C) IL-15, (D) 
TNF-α, (E) IL-6, (F) IL-18, (G) IL-10, (H) IL-2, and (I) IFN-γ compared to the (A) cFIX 
expression levels as measured by % cFIX activity in the three HB dogs (Wiley, red, right 
Y axis for % activity; Trex, blue; Wick, green) at baseline and following delivery of 
AAV.  Grey bars indicate level of detection of the assay.   
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inhibitory antibodies to cFIX without systemic toxicity. 
 
Cytokine profile following AAV-cFIX-Padua liver gene therapy and FIX inhibitor 
eradication 
Cytokine profiles can be useful in tracking immune responses and suggesting 
immunologic mechanisms.  Therefore, we ran a multiplex array on plasma from the three 
dogs looking at 8 cytokines, with a focus on T cell cytokines (Figure 3.5).  Wick did not 
have detectable cytokine levels for any of the time points assayed.  Trex showed a spike 
on day 3 following vector administration of CM-CSF, IL-15, TNF-α, IL-6, and IL-18, as 
well as small spikes of IL-10 and IFN-γ (Figure 3.5B-G).  Interestingly, he also showed 
high levels of GM-CSF, IL-15, IL-6, and IL-18 on day 70 (Figure 3.5B,C,E,F).  This did 
not correlate with any loss of cFIX expression or activity, detection of anti-cFIX IgG or 
BU, or prolongation of the WBCT (Figure 3.1, 3.3, 3.5A).  Wiley’s levels of GM-CSF, 
IL-15, IL-6, and IL-18 (Figure 3.5B,C,E,F) inversely correlated to his cFIX activity 
levels (Figure 3.5A).  Conversely, he had relatively low levels of TNF-α and IL-2 
throughout, with a small spike in the latter at day 27 (Figure 3.5D,H).  Wiley’s IL-10 
levels climbed from weeks 2-4, generally falling thereafter until he was challenged on 
day 840, at which point levels began to rise again (Figure 3.5G).  IFN-γ showed a 
bimodal distribution, with an early peak at week 4 followed by a late peak following the 
recombinant protein challenge (days 847-860) (Figure 3.5I). 
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A B 
Figure 3.6 Markers of coagulation activation in HB dogs following liver delivery of 
AAV-cFIX-Padua. All three dogs were assessed for (A) thrombin anti-thrombin 
complexes (TAT) and (B) D-dimers as markers of coagulation at baseline and time points 
following AAV administration using ELISAs.  Horizontal dotted line indicates the limit 
of detection of the TAT ELISA (2 ug/L).  Grey bar indicates normal range (<11.7 ug/L 
TAT and <500 ng/mL d-dimer). 
 
 
Risk of thrombogenicity of long-term expression of FIX-Padua 
Expression of FIX-Padua is associated with improvement of the disease phenotype as 
noted by the normalization of WBCT (Figures 3.1,3.4), TEG parameters (Figure 3.2; 
Table 3.2), and the lack of bleeding episodes following AAV delivery (Table 3.1). 
 
In both dogs expressing FIX in the range of mild hemophilia (Wick and Trex), we 
measured TAT complex and D-dimer levels at different time points and no abnormal  
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Figure 3.7 Humoral responses to AAV8 capsid in HB dogs following liver delivery of 
AAV-cFIX-Padua. All three dogs were assessed for anti-AAV8 (A) IgG1 and (B) IgG2 
antibodies at baseline and time points following AAV administration using anti-AAV8 
IgG ELISAs. 
 
 
elevation in the levels were detected 202, 208, consistent with a lack of clinically recognized 
thrombosis (Figure 3.6).  Notably, data from the dog Wiley showed continuous 
expression of supraphysiologic levels of FIX-Padua after inhibitor eradication for over 
400 days and yet presented no clinical evidence of peripheral thrombosis. TAT and D-
dimer levels remain within normal limits 202, 208 (Figure 3.6).  These data suggest that the 
risk of thrombogenicity of FIX-Padua is low at a wide range of expression levels. 
 
Humoral responses to AAV 8 capsid 
All dogs developed a robust and sustained anti-AAV8 capsid immune response measured 
by increase in IgG2 and, to a lesser extent, IgG1 levels (Figure 3.7).  These data indicate 
that these dogs are capable of generating sustained immune responses to other antigens,   
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Figure 3.8 Humoral responses to hFIX-Padua following challenge. 10-15 weeks after 
administration of 5 x 1010 vg/kg AAV8-hFIX-R338L or AAV-hFIX-WT, HB mice were 
assessed for development of anti-hFIX IgG antibodies following subcutaneous challenges 
with 2 ug per mouse of recombinant hFIX-WT or hFIX-Padua with protein alone, protein 
with CFA, and protein with IFA.  Untreated HB mice challenged with protein alone 
served as a positive control.  ** p < 0.01; *** p < 0.001. 
 
 
 
 
such as vector capsid, excluding the possibility of a general state of defective immune 
responses. 
 
Murine Studies 
Lack of immune responses to hFIX-Padua in HB mice by AAV liver gene therapy 
Adult HB mice (n=9-11 mice/group) received injections of AAV encoding either hFIX-
Padua or hFIX-WT resulting in similar circulating FIX plateau antigen levels (724 ± 116 
ng/ml and 850 ± 96 ng/ml, respectively). Mice expressing hFIX-WT received 
recombinant hFIX-Padua protein and conversely, mice expressing hFIX-Padua were 
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challenged with hFIX-WT protein. Initial challenges started at week 10 post vector 
administration, followed by an additional dose every week for three weeks.  No antibody 
to hFIX was detected by anti-hFIX total IgG (Figure 3.8) or Bethesda assay (data not 
shown).  Further challenges with hFIX-Padua or hFIX-WT in CFA or in IFA failed to 
trigger immune responses to either hFIX forms (Figure 3.8). In contrast, naïve HB mice 
(n=4-5) develop antibodies to hFIX upon exposure to protein alone, even without 
adjuvant (Figure 3.8). Thus, upon stringent immunologic challenges with reciprocal 
protein no antibody formation was detected in these mice suggesting that the 
immunogenicity of FIX-Padua is comparable to that of FIX-WT. 
 
Long-term expression and toxicity of FIX-Padua is comparable to FIX-WT 
To assess whether expression of hFIX-Padua is associated with abnormal activation of 
coagulation or early death, hemostatically normal C57Bl/6 male mice received increasing 
vector doses encoding hFIX-Padua or hFIX-WT. As expected, hFIX specific activity was 
7-10 fold-higher in the hFIX-Padua compared to hFIX-WT expressing mice (data not 
shown). We grouped mice expressing FIX-Padua or FIX-WT according to the FIX 
activity at low (100-230%) and high (480-2020%) cohorts. A time course of TAT 
complex levels show no difference between the FIX forms and no increase in TAT levels 
over time (Figure 3.9A-B).  D-dimer levels increased as a function of time only for the 
low dose cohorts of hFIX-WT (p=0.0002) and hFIX-Padua (p=0.006), but there was no 
difference in D-dimer levels between the two FIX variants (Figure 3.9C-D).  No changes 
in D-dimer levels were observed over time for the control group. Kaplan-Meier survival  
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Figure 3.9 Markers of coagulation activation in wild type C57BL/6 mice expressing 
hFIX-WT and hFIX-Padua at supraphysiologic levels following AAV. Mice 
expressing hFIX-WT, white bars, and hFIX-Padua, black bars, at levels resulting in (A,C) 
100-230% activity and (B,D) 480-2020% activity were assessed for (A,B) thrombin anti-
thrombin complexes (TAT) and (C,D) D-dimers as markers of coagulation 2, 5 (TAT 
only) and 8 months following vector administration.  At no point were there statistically 
significant differences between the hFIX-WT and hFIX-Padua expressing groups. Grey 
bars, empty capsid treated control animals with normal FIX levels. 
 
 
analysis showed no difference between mice expressing hFIX-Padua or hFIX-WT 
(Figure 3.10).  Early death was associated with supraphysiologic levels only after 8-10 
months post vector injection. Moreover, data from the control group (AAV empty capsid) 
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Figure 3.10 Survival of wild type C57BL/6 mice expressing hFIX-WT and hFIX-
Padua at supraphysiologic levels following AAV. Mice expressing hFIX-WT, grey 
lines, and hFIX-Padua, black lines, at levels resulting in (A) 100-230% activity and (B) 
480-2020% activity did not have different survival rates.  Black dotted line, empty capsid 
treated control animals with normal FIX levels. 
 
 
show no death during the study. Together, these findings suggest that the long-term 
toxicity in mice expressing a wide range of expression of hFIX-Padua is comparable of 
that of hFIX-WT. 
 
IV. Discussion 
One of the major safety concerns in developing novel therapies based on protein, cell, or 
gene therapy for hemophilia is the formation of antibodies to the missing clotting factors. 
The presence of these antibodies renders the replacement therapy ineffective with 
increased morbidity and mortality. 209, 210, 211 Experiences with protein replacement 
therapy demonstrate that manufacturing procedures, mismatches between the therapeutic 
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protein sequence and rare haplotypes in the host, and modifications on the amino acid 
sequence could all influence the rates of inhibitor formation. 180, 212, 213, 214  Here we 
sought to test the safety of liver-restricted expression of the cFIX-Padua variant. Severe 
HB dogs with an underlying F9 gene null mutation exhibit a high risk of antibody 
formation upon exposure to cFIX-WT, and thus provide an excellent model to test the 
immune responses to the neotransgene. The data presented in HB dogs clearly 
demonstrate that AAV liver gene therapy ensures sustained expression of cFIX-Padua 
(25%-300% of normal) with high specific activity (8-12 fold) consistent with the findings 
in humans hemizygous for FIX-Padua. 189  We observed complete normalization of 
WBCT and TEG values concomitant with a lack of bleeding episodes over a long-term 
follow up in naïve HB dogs and after eradication of cFIX inhibitors in the dog Wiley.  
 
Early-phase clinical trials for men with severe HB using AAV2 or AAV8 vectors showed 
that in the high dose cohort (2 x1012 vg/kg) therapeutic levels of hFIX-WT were achieved 
with transient liver immune-mediated toxicity 183, 188 controlled by a short-term course of 
immunosuppression 183.  Here we achieved therapeutic levels of FIX activity (25-200%) 
well above the minimal target of 5% at vector doses of 1 x 1012 or 3 x 1012 vg/kg; 
therefore, it is reasonable to suggest that lower doses of AAV will be able to achieve 
therapeutic levels using FIX-Padua as the transgene.  Surprisingly, we did not see the 
normally-observed AAV dose response in FIX expression.  Specifically, the expression 
in Trex was quite poor compared to Wiley, who received the same dose, and even less 
than Wick, who received one third as much vector.  Two things may account for this 
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relatively low expression.  First, Trex is notably smaller than Wiley, resulting in a lower 
total vector dose.  Secondly, the spike in Trex of GM-CSF and IL-15 (pro-inflammatory 
cytokines) and IL-18, IL-6, and TNF-α (Th2 and Th1 cytokines) at day 3 following 
vector administration is suggestive of a memory T cell response induced by AAV 
administration.  This could indicate a prior exposure to AAV and potentially signify the 
presence of low titers of anti-AAV antibodies that we were unable to detect in our assay, 
but that could still partially inhibit AAV transduction. 
 
In addition to high specific activities, we showed that liver expression of cFIX-Padua 
induced tolerance in these dogs and did not generate any anti-FIX humoral immune 
responses, even after challenge with cFIX-WT protein concentrate at doses associated 
with inhibitor formation in naïve HB dogs from this colony. 193  The expression of FIX-
Padua showed no increased immunogenicity upon exposure to FIX-WT protein 
concentrate, which mimics the clinical scenario in which patients expressing FIX-Padua 
by AAV vectors (ongoing and planned clinical studies) may require protein replacement 
to control major bleeding or to prepare for large invasive procedures. 
 
Notably, our data also showed that expression of AAV-cFIX-Padua was successful in 
eradicating inhibitory antibodies that had been triggered by previous exposure to 
recombinant human FIX and cross reacted to cFIX. We documented an amnestic 
response (peak titers ~5 BU) at early time points after AAV injection followed by 
eradication of the anti-cFIX antibodies and a gradual increase in the circulating levels of 
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fully active cFIX-Padua. The lack of immune response to the transgene was maintained 
after challenge with FIX-WT protein concentrate, reinforcing the strength with which 
AAV liver gene transfer induces transgene-specific immune tolerance. No kidney, liver 
or systemic toxicity was observed in this dog over a period of >2 years (ongoing 
observations). Of note, the inhibitory antibody (BU) to human FIX was completely 
eradicated, whereas residual non-neutralizing antibodies (IgG2) declined but are still 
detectable. This probably reflects that immune tolerance occurred to epitopes shared by 
canine and human FIX but not those restricted to human FIX, and thus this strategy is 
likely to epitope specific. The findings in this HB dog are the first demonstration of 
eradication of inhibitors to FIX in a large and immune competent HB model with pre-
existing antibodies to FIX. 
 
The time course for eradication of inhibitor and detection of circulating FIX levels in this 
dog was similar to our early data in immune tolerance induction by AAV expressing 
canine FVIII in hemophilia A dogs with pre-existing inhibitors (Chapter 2) 215.  Despite 
the fact that detectable anti-FIX IgG2 resolved in 70 days, FIX activity took nearly 800 
days to plateau.  This suggests there were anti-FIX antibodies that our assay was unable 
to detect —perhaps residual poorly cross-reacting anti-hFIX, which likewise reached the 
limit of detection and plateau around day 800.  Interestingly, Wiley’s cytokine profile 
may reflect this.  He initially showed high levels of GM-CSF, IL-15, and IL-18, markers 
of an inflammatory immune response, as well as IL-6, suggesting a Th2 immune 
response as would be expected for inhibitors.  These cytokines gradually decreased over 
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the next 800+ days concurrent with a rise in FIX activity.  In comparison, the Th1 
effector cytokine TNF-α was largely undetectable in Wiley.  Wick, conversely, had no 
detectable cytokines throughout the period he was monitored, implying Wiley’s cytokine 
response is not in response to AAV.  This, combined with the rise in FIX during this 
period, suggests that the cytokine profile seen in Wiley is indicative of an ongoing Th2-
based, anti-FIX response that is slowly resolving.  We did note elevated cytokines in Trex 
on day 70 following AAV administration but with no loss of cFIX expression or activity 
or detection of anti-cFIX antibodies.  There is nothing to indicate that this isolated 
immune response is related to AAV administration or cFIX-Padua expression and may 
simply have been due to an unnoticed illness.  Other that this peak and the 
aforementioned peak on day 3, Trex did not have elevated cytokines as was seen with the 
inhibitor dog Wiley. 
 
Despite the inflammatory T cell response occurring at the early time points in Wiley, 
there is a striking lack of IL-2.  When coupled with the expression of IL-10, this is 
suggestive of a possible regulatory T cell (Treg) response.  In the FVIII inhibitor dog 
model described in Chapter 2, we likewise observed a transient increase in the pool of 
canine regulatory T cells (CD4+CD25+FoxP3+ T cells) peaking one to two weeks after 
vector delivery and immediately preceding the disappearance of antibodies.  In Wiley, 
IL-10 expression rose during weeks 2 through 4, and then, interestingly, again following 
the protein concentrate challenge, suggesting Tregs were again required to control an 
anti-cFIX immune response.  Also of interest is the kinetics of the IFN-γ immune 
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response seen in Wiley.  There were two distinct peaks, one in the weeks immediately 
following vector administration and another following challenge with FIX protein 
concentrate.  While normally considered to be a cytotoxic T cell and Th1 cytokine, recent 
papers have suggested that IFN-γ can also be transiently produced by or required for the 
conversion of induced Tregs (iTregs) 216, 217—specifically, Tregs converted from 
CD4+CD25- T cells into CD4+CD25+FoxP3+ Tregs in the periphery.  Given that we are 
not inducing central tolerance through the thymus, conversion of CD4+ effector T cells 
into iTregs would be the expected mechanism of Treg development in these models.  The 
second peak in IFN-γ post-challenge, like the rise in IL-10, suggests that Tregs were 
again called upon to squelch an anti-cFIX immune response.  This could partially explain 
the remaining question of the mechanism of long-lasting AAV-induced tolerance. 
 
In this HA model, we showed that IgG2 was the predominant IgG subclass 215.  The 
human equivalent of canine IgG2 is IgG4, and both are associated with a type 2 helper 
CD4+ T cell response 196.  IgG4 exhibits unique properties and posttranslational 
modifications compared to other IgGs; notably IgG4 has poor affinity to Fc receptor and 
for C1q of the complement pathway, thus preventing cell and complement activation, 
respectively. 218  Recently, IgG4 production has been linked with activation/generation of 
CD4+ regulatory T cells and thus with a potential for down-modulated immune responses 
219, 220.  Therefore, it is possible that in the context of inhibitors to FIX in this canine 
model, a similar immune tolerance induction mechanism was associated with inhibitor 
eradication. 
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Data on additional dogs with pre-existing inhibitors to FIX are certainly needed to 
confirm this early successful observation and to more clearly define the underlying 
mechanism of immune tolerance. The success rates of immune tolerance induction 
protocols using frequent injections of FIX protein concentrates are lower than those for 
hemophilia A, and potential complications such nephrotic syndrome, allergic and 
anaphylactic reactions all hamper the overall safety 178, 207, 221.  It is possible that AAV-
based immune tolerance induction could also be indicated for a selected group of HB 
patients with inhibitors to FIX who are currently excluded from clinical trials. 
 
The immune competent status of these three dogs was confirmed by the humoral 
responses to the vector capsid proteins. All dogs developed anti-AAV capsid IgG2 and 
IgG1. Similar findings were observed in humans following AAV2 or AAV8 delivery to 
the liver in which IgG subclasses were IgG1 and IgG2 188, 222 or mostly IgG1, respectively 
183.  Thus this strategy to use AAV for the transgene-specific immune tolerance does not 
induce a general status of immunosuppression. 
 
Finally, studies in mice allow us to compare the immunogenicity of FIX-Padua with FIX-
WT in a stringent manner. Mice expressing FIX-Padua or FIX-WT failed to mount an 
immune response to the reciprocal recombinant FIX proteins, even when mixed with 
adjuvants to enhance immune responses. 
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The potential thrombogenicity of continuous expression of FIX-Padua appears to be 
minimal, as no evidence of pathological activation of coagulation or clinical evidence of 
thrombosis was noted in any of the three dogs with a cumulative observation of ~ 6 years, 
despite Wiley’s high FIX activity levels. Together with the lack of thrombosis in another 
group of three HB dogs expressing FIX-Padua following AAV delivery to skeletal 
muscle for a cumulative 5 years 200, there is no evidence of thrombosis in a total of 6 dogs 
for a combined 11 year-period, suggesting a very low risk for such a complication. This 
is expected considering that thrombosis occurred only in FIX-Padua patients with activity 
levels >700% of normal, which is significantly higher than the FIX levels in these dogs, 
and not in a heterozygous patient with 300-400% activity 189.  
 
The comparable safety of FIX-Padua to FIX-WT is further supported by longitudinal 
studies in mice expressing FIX-Padua or FIX-WT, which showed similar profiles of 
activation of coagulation and survival rates. These data are agreement with previous 
short-term gene therapy studies in mice 223.  The main determinant of pathological 
coagulation and death rates was the supraphysiologic levels of either FIX forms that 
occur in a time-dependent manner, i.e. after 8-10 months post vector injection, thus 
providing more stringent risk assessment than short-term studies.  These data suggest that 
the safety of continuous expression of FIX-Padua does not differ from the FIX-WT 
expression and, thus FIX-Padua is not inherently more thrombogenic per se, but at 
extremely high levels behaves in a similar fashion as FIX-WT. 
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Collectively the efficacy and safety data from dogs and mice expressing FIX-Padua form 
the basis for translational studies. The safe immunological profile of FIX-Padua in the 
inhibitor-prone dogs would allow the inclusion of HB patients with F9 gene null 
mutations in gene therapy clinical trials. 
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CHAPTER 4 
ACTIVATED PROTEIN C’S ANTI-METASTATIC PROPERTIES ARE 
INDEPENDENT OF ANTICOAGULATION AND CYTOPROTECTION 
 
 
I. Introduction 
Activated protein C (aPC) is a vitamin-K dependent serine protease with anticoagulant 
and cytoprotective functions.  Thrombin generated by the coagulation cascade complexes 
with thrombomodulin (TM) and cleaves zymogen protein C (zyPC) bound to the 
endothelial protein C receptor (EPCR), converting it to aPC 224.  aPC, in conjunction with 
its cofactor protein S (PS) 224, 225, can then cleave FVa and FVIIIa, inactivating them and 
inhibiting the clotting cascade. 226 
 
aPC also has cytoprotective and anti-inflammatory effects on the endothelium through 
protease activated receptor 1 (PAR-1) and downstream sphingosine-1 phosphate receptor 
1 (S1P1) mediated cell signaling 227, 228, 229.  This results in anti-apoptotic signals, 
downregulation of pro-inflammatory cytokines and receptors, and enhanced barrier 
function in the vascular endothelium 227. 
 
In addition to it anticoagulation and cytoprotective functions, aPC has been shown to 
have anti-metastatic effects both in vitro and in vivo 230, 231.  Coagulation and thrombin 
generation are known to enhance metastasis 232, 233, while hirudin, a potent inhibitor of 
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thrombin, reduces metastasis 234, 235, suggesting that aPC’s anticoagulant activity may be 
responsible for its ability to modulate cancer progression.  Conversely, previous work has 
indicated that endogenous aPC’s anti-metastatic properties stem, instead, from its 
cytoprotective effect mediated through the PAR-1/S1P1 pathway 231.  However, the 
mechanism of action of exogenous aPC’s ability to reduce tumor metastasis even further 
have not been explored.  Here, we examine the ability of elevated levels of aPC following 
gene therapy to greatly reduce the number of pulmonary metastatic lesions in the B16F10 
murine melanoma model and attempt to ascertain if protection against cancer progression 
is due to the anticoagulant or the cytoprotective functions of aPC. 
 
II. Materials and Methods 
Animals 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee at the Children's Hospital of Philadelphia.  Eight-week-old, male C57Bl/6 
mice were obtained from Jackson Laboratories.  Protein C-deficient mice on the C57Bl/6 
background 236 were generously provided by the laboratory of Francis Castellino at the 
University of Notre Dame and were maintained at the Children’s Hospital of Philadelphia 
according to institutional guidelines. 
 
Cell culture 
B16F10 murine melanoma cells (ATCC) were cultured in 1:1 DMEM/F12 (Gibco) 
supplemented with 10% fetal bovine serum (Gibco),1% antibiotic-antimycotic 
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(penicillin-streptomycin-Fungizone, Gibco), and 1% L-glutamine at 37°C with 5% CO2.  
Single cell suspensions were prepared for injection by washing cells 3 times with 
phosphate buffered saline (PBS) followed by 3 µM EDTA and 3 more PBS washes.  
Cells were then filtered, counted, resuspended in PBS, and stored on ice until injection. 
 
Recombinant AAV vector 
Production of AAV serotype 8 vectors was carried out by the Center of Cellular and 
Molecular Therapeutics’ vector core at the Children’s Hospital of Philadelphia as 
previously described 237.  The expression cassette contained wild type or mutant murine 
protein C with or without a PACE/Furin cleavage site motif encoded 3’ of the activation 
peptide (proteins with the PACE/Furin site added are cleaved intracellularly and secreted 
as activated protein C) behind three copies of the liver-specific ApoE enhancer region 
and the liver-specific human alpha-1 anti-trypsin (hAAT) promoter 237.  Null vector 
consisted of human factor IX with an early stop codon behind the same 
promoter/enhancer. 
 
Pulmonary metastasis model 
1 x 1011 vg/kg to 1 x 1014 vg/kg (5 x 1013 vg/kg for all experiments where dose was not 
specified) of AAV8 in 200 µL PBS was injected intravenously via lateral tail vein in 
mice on a C57Bl/6 background.  Three weeks later, blood was collected via tail bleeds 
into 3.8% sodium citrate, and plasma was removed and frozen for later analysis.  2.5 x 
105 B16F10 cells resuspended in 200 µL PBS (1.25 x 106 cells/mL) were injected 
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intravenously via lateral tail vein as previously described 238.  After 21 days mice were 
sacrificed by CO2 asphyxiation, blood was collected from the vena cava into 3.8% 
sodium citrate, and lungs were perfused with 4% paraformaldehyde via the trachea prior 
to removal and storage in 4% paraformaldehyde at 4°C.  Lung lobes were then separated 
and tumor foci visible with the naked eye were quantified by two independent, blinded 
observers. 
 
Quantification of murine aPC and zyPC  
Murine aPC plasma levels were assayed by capture ELISA as previously described 239, 240.  
Plates were coated with monoclonal anti-maPC capture antibody 1582 provided by 
Charles Esmon and blocked with 1% BSA/PBS.  Samples were diluted 1:4 in blocking 
buffer and incubated overnight at 37°C; standards were diluted recombinant murine aPC, 
also provided by Charles Esmon.  Plates were developed using the Spectrozyme PCa 
chromogenic substrate (American Diagnostica). 
 
Murine zyPC levels were determined one of two ways.  In the first, zyPC was activated 
with Protac (American Diagnostica) and assayed as above but using Spectrozyme aPC 
(American Diagnostica) as the chromogenic substrate.  Alternatively, a traditional 
sandwich ELISA was performed using monoclonal antibody AMPC-9071 rat anti-murine 
PC (Haematologic Technologies, Inc) at 10 µg/mL in PBS to coat and 2% BSA/0.05% 
Tween-20/PBS to block a 96 well-plate.  Standards were recombinant murine zyPC 
provided by Giulia Pavani and Paris Margaritis diluted in 1:4 human protein C-deficient 
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plasma (George King Bio-Medical, Inc):blocking buffer and samples were also diluted 
1:4 in blocking buffer.  Polyclonal sheep anti-murine PC PAMPC-S (Haematologic 
Technologies, Inc) conjugated with HRP diluted 1:600 in blocking buffer served as the 
secondary antibody.  Plates were developed with OPD/hydrogen peroxide/sodium citrate 
solution. 
 
Activated partial thromboplastin time (aPTT) 
aPTTs were performed by incubating 50 µL sample plasma with 50 µL TriniCLOT 
Automated aPTT reagent for 3 minutes at 37°C, following by the addition of 50 µL of 25 
mM calcium chloride and measuring time to clot formation with a fibrometer. Plasma 
from hemostatically normal C57BL/6 mice typically clots in 27.3 to 32.4 seconds (30.1 ± 
1.88 seconds on average) as previously reported by members of our group 241. 
 
Tail clip assay 
Tail clip assays were performed as previously described 241.  Briefly, tails were placed in 
37°C normal saline for two minutes and then transected at a 3 mm diameter.  Tail was 
immediately placed in 14 mL 37°C normal saline and allowed to bleed/clot freely for 10 
minutes.  Tail was then removed and sutured.  Blood was pelleted, then lysed in 6 mL 
lysis buffer, and blood loss was quantified by measuring absorbance of 575 nm light as 
previously described 242. 
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Statistical analysis 
Statistics were run using GraphPad Prism (GraphPad Software Inc).  Graphs indicate the 
mean plus and minus the standard deviation.  Unpaired, one-tailed Welch's t-tests were 
used to compare treated groups to PBS control mice, and unpaired, two-tailed Welch's t-
tests were used to compare variant treated groups to positive control wild type a/zyPC 
treated groups.  P values <0.05 were considered statistically significant. 
 
III. Results 
Dose-dependent protection against metastasis with activated protein C 
Wild type C57Bl/6 mice were administered 1 x 1012 to 1 x 1014 vg/kg AAV8 encoding 
murine aPC behind a liver-specific promoter enhancer.  Mice receiving the lowest dose of 
1 x 1012 vg/kg expressed 7.29 ± 3.0 ng/mL aPC (~4 fold over endogenous levels), which 
was not enough to protect against tumor metastasis in the B16F10 melanoma model 
(Figure 4.1).  However, mice receiving the mid dose, 1 x 1013 vg/kg, and the high dose, 1 
x 1014 vg/kg, expressed aPC at levels ~7 fold and ~28 fold over endogenous, respectively, 
and showed an increasing reduction in the number of pulmonary tumor foci compared to 
control mice administered PBS in lieu of AAV (Figure 4.1). 
 
Determining metastasis with activated protein C anticoagulant-deficient variants 
aPC-L38D has a missense mutation in the Gla domain at the amino acid responsible for 
PS binding, ablating PS cofactor function 243 and slightly reducing anticoagulant activity 
compared to wild type aPC at high doses (Figure 4.2A).  aPC-L38D retains the capacity   
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Figure 4.1 aPC expression reduces pulmonary tumor formation in a dose-dependent 
manner.  Mice were administered 1 x 1012 to 1 x 1014 vg/kg AAV8-hAAT-maPC or PBS 
intravenously three weeks prior to intravenous injection of 2.5 x 105 murine B16F10 
cells.  Lungs were removed 21 days later and pulmonary tumor foci visible to the naked 
eye were quantified.  Significance is comparing the treated group to the control group for 
each dose experiment.  Red values over each bar indicate the average level ± SD of 
maPC as determined by capture ELISA.  Small bold black value indicate the fold 
increase of maPC levels in treated group compared to control group for each dose 
experiment.  Number at the bottom of each bar indicates the number of mice in that 
group.  * p < 0.05; ** p < 0.01; error bars indicate SD. 
 
 
to bind to EPCR and cytoprotective signaling via the PAR-1 pathway 243.  It also retains 
the anti-metastatic properties of wild type aPC, significantly reducing the number of 
pulmonary tumors formed in the B16F10 metastasis model compared to PBS controls, 
with no statistical difference compared to the number of tumors in wild type aPC-
expressing mice (Figure 4.2C).  aPC-5A, on the other hand, consists of 5 amino acid   
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Figure 4.2 Coagulation-deficient aPC-L38D retains the anti-metastatic protective 
effect, but cytoprotective aPC-5A does not.  (A,B) Groups of five mice were 
administered 5 x 1013 vg/kg AAV8-maPC (red bars) or 1 x 1012 (low dose, LD), 1 x 1013 
(mid dose, MD), or 5 x 1013 (high dose, HD) vg/kg AAV8-maPC-L38D (purple bars) or 
AAV8-maPC-5A (orange bars).  Citrated plasma was then collected and run in an aPTT.  
Horizontal dotted line indicates average clotting time of wild type mice.  Significance 
indicates differences between the indicated group and the AAV8-maPC group.  (B) Mice 
were administered 5 x 1013 vg/kg AAV8-maPC, -maPC-L38D, -maPC-5A or PBS 
intravenously three weeks prior to intravenous injection of 2.5 x 105 murine B16F10 
cells.  Lungs were removed 21 days later and pulmonary tumor foci visible to the naked 
eye were quantified.  Significance is comparing the treated groups to the PBS control 
group.  Horizontal bars indicate mean.  Photographs are of a representative set of lungs.  
* p < 0.05; ** p < 0.01; *** p < 0.001; ns, not signficant 
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changes in the protease domain, RR229-230AA and KKK191-193AAA 244, 245, which 
leads to near complete loss of anticoagulant function (Figure 4.2B) but, again, intact 
cytoprotective effects.  This has proven to be beneficial in sepsis models, as anti-septic 
cytoprotective function is retained with a greatly reduced risk of bleeding.  However, the 
5A mutations also render aPC unable to protect against tumor metastasis, with no 
statistical difference in the number of tumors formed in the treated animals versus PBS 
controls (Figure 4.2C). 
 
In order to further characterize the loss of metastasis protection in the aPC-5A variant, we 
divided the five mutations into two, making the aPC-3A (KKK191-193AAA) mutant and 
the aPC-2A (RR229-230AA) mutant, and tested their effectiveness in the B16F10 
metastasis model.  Murine aPC-2A, -3A, and -5A have been shown to retain just 33, 25, 
and 8% of normal aPC anticoagulant function, but have no loss in cytoprotective function 
246.  Interestingly, the more anticoagulant function retained, the better the aPC variants 
were able to reduce tumor metastasis (Figure 4.3B).   
 
Dose-dependent protection against metastasis with zymogen protein C 
With loss of anticoagulant function having no negative impact on anti-metastatic function 
of aPC in one variant (L38D) and complete ablation of anti-metastatic function in another 
(5A), we endeavored to determine if the loss of protection seen with the aPC-5A, -3A and 
-2A variants was caused by the loss of anticoagulation or if it was merely correlative.  To  
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A Figure 4.3 Loss of anti-metastatic 
effect of aPC correlates with loss of 
anticoagulant function in aPC-2A, -
3A and -5A mutants.  (A) Groups of 
five mice were administered 5 x 1013 
vg/kg AAV8-maPC (red bars) or 1 x 
1012 (low dose, LD), 1 x 1013 (mid dose, 
MD), or 5 x 1013 (high dose, HD) vg/kg 
AAV8-maPC-5A (green bars), AAV8-
maPC-3A (purple bars) or AAV8-
maPC-2A (orange bars).  Citrated 
plasma was then collected and run in an 
aPTT.  Horizontal dotted line indicates 
average clotting time of wild type mice.  
Significance indicates differences 
between the indicated group and the 
AAV8-maPC group.  (B) Mice were 
administered 5 x 1013 vg/kg AAV8-
maPC, -maPC-5A, -maPC-3A, -maPC-
2A or PBS intravenously three weeks 
prior to intravenous injection of 2.5 x 
105 murine B16F10 cells.  Lungs were 
removed 21 days later and pulmonary 
tumor foci visible to the naked eye were 
quantified.  Significance is comparing 
the treated groups to the PBS control 
group or the AAV-maPC group.  
Horizontal bars indicate mean ± SD.   
* p < 0.05; ** p < 0.01; ns, not 
significant 
 
 
 
do this, we examined zyPC’s ability to protect against tumor metastasis in a dose-
dependent manner.  Zymogen PC does not have inherent anticoagulant activities (Figure 
4.4), although there is literature supporting the idea that zyPC has cytoprotective 
functionality 247.  Even at high expression levels, zyPC did not prolong aPTT compared to 
wild type plasma, while just low doses of aPC did (Figure 4.4).  Additionally, high  
B 
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Figure 4.4 zyPC does not have anticoagulant activity.  Groups of 5 mice were injected 
with 1 x 1014 vg/kg (HD) AAV8-mzyPC (green bars) or –maPC (dark red bars), 1 x 1013 
vg/kg (MD) AAV8-maPC (red bars), 1 x 1012 vg/kg (LD) AAV8-maPC (pink bars), or 
PBS (blue bars).  (A) Citrated plasma was collected and used in an aPTT.  (B) Blood loss 
following a tail clip assay was determined by lysing the lost blood and reading 
absorbance with 575 nm light. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant. 
 
 
expression levels of aPC but not zyPC increased blood loss in animals in a tail clip assay 
(Figure 4.4). 
 
Wild type C57Bl/6 mice were again administered 1 x 1012 to 1 x 1014 vg/kg AAV8, this 
time encoding murine zyPC behind a liver-specific promoter enhancer.  To measure 
zyPC levels, plasma was first treated with Protac to activate any zyPC, and then aPC 
levels were measured.  Mice receiving the lowest dose of 1 x 1012 vg/kg showed levels 2-
3 fold over endogenous (this fold increase was confirmed with a zyPC-specific antigen 
ELISA, which showed the LD group expressing zyPC at levels 2.9x over wild type), 
which, interestingly, was adequate to protect against tumor metastasis in the B16F10  
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Figure 4.5 zyPC expression reduces pulmonary tumor formation at doses lower than 
aPC. Mice were administered 1 x 1012 to 1 x 1014 vg/kg AAV8-hAAT-mzyPC or PBS 
intravenously three weeks prior to intravenous injection of 2.5 x 105 murine B16F10 
cells.  Lungs were removed 21 days later and pulmonary tumor foci visible to the naked 
eye were quantified.  Significance is comparing the treated group to the control group for 
each dose experiment.  Red values over each bar indicate the average level ± SD of 
maPC as determined by capture ELISA after zyPC activation with Protac.  Small bold 
black value indicate the fold increase of maPC levels in treated group compared to 
control group for each dose experiment.  Number at the bottom of each bar indicates the 
number of mice in that group.  ** p < 0.01; error bars indicate SD. 
 
 
 
 
melanoma model (Figure 4.5).  Such protection had not been seen in the low dose of aPC 
vector administration, which had required the mid dose and 6-7 fold over endogenous 
levels before there was a statistical anti-metastatic effect (Figure 4.1).  There was an 
increasing reduction in the number of pulmonary tumor foci as zyPC vector doses 
increased correlating with increased expression (Figure 4.5).  An even lower dose of 1 x 
1011 vg/kg AAV-mzyPC resulting in expression levels equal to just 150% endogenous  
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Figure 4.6 Endogenous zyPC modulates metastatic tumor formation.  Untreated 
protein C-deficient mice expressing <15% normal zyPC levels (red line) and wild type 
littermate controls (blue line) were injected intravenously with 2.5 x 105 murine B16F10 
cells and monitored daily.  Remaining mice were sacrificed 21 days later.  Lungs were 
removed from all mice following death.  Photographs are of a representative set of lungs. 
 
 
 
levels was inadequate to protect against metastasis (data not shown). 
 
To further support the involvement of zyPC in preventing metastasis, we used a murine 
model deficient in PC.  Antigen ELISAs performed by our lab show these mice express 
approximately 5-15% of normal zyPC levels.  When injected with B16F10 cells without 
prior treatment, PC-deficient mice all died by day 20 while their wild type littermate 
controls survived for the duration of the 21 day experiment (Figure 4.6).  Additionally, 
while the wild type mice had typical pulmonary tumor counts ranging from 50 to 200, the 
number of tumors in the lungs of the PC-deficient mice were so numerous as to be 
unquantifiable (see photo in Figure 4.6). 
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Figure 4.7 Activation- and catalytic site-deficient zyPC-R15Q and zyPC-S195A 
retain the anti-metastatic protective effect. Mice were administered 5 x 1013 vg/kg 
AAV8-mzyPC (A&B, green), -mzyPC-R15Q (A, yellow), -mzyPC-S195A (A, purple), -
mzyPC-R15QS195A (B, purple) or PBS (A&B, blue) intravenously three weeks prior to 
intravenous injection of 2.5 x 105 murine B16F10 cells.  Lungs were removed 21 days 
later and pulmonary tumor foci visible to the naked eye were quantified.  Significance is 
comparing the treated groups to the PBS control group in each experiment.  Horizontal 
bars indicate mean ± SD.  * p < 0.05; ** p < 0.01. 
 
 
zyPC protection against metastasis is not a result of local conversion to aPC 
While zyPC does not have any inherent anticoagulant activity, it is possible that the high 
levels of circulating zymogen meant an increase in aPC conversion and thus 
anticoagulation at sites of tumor metastasis.  To explore this possibility, we used mice 
expressing the zyPC-R15Q mutant, which lacks the ability to dock to the thrombin-
thrombomodulin complex and therefore cannot be cleaved 248, or zyPC-S195A, a 
mutation of the catalytic serine in the active site.  Both retained the ability to protect 
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Figure 4.8 Loss of protection with 5A mutations is not due to loss of anticoagulation. 
Mice were administered 5 x 1013 vg/kg AAV8-mzyPC (squares), -mzyPC-5A (triangles), 
or PBS (circles) intravenously three weeks prior to intravenous injection of 2.5 x 105 
murine B16F10 cells.  Lungs were removed 21 days later and pulmonary tumor foci 
visible to the naked eye were quantified.  Significance is comparing the treated groups to 
the PBS control group.  Horizontal bars indicate mean ± SD.  *** p < 0.001. 
 
 
against tumor metastasis, as did the double mutant zyPC-R15QS195A, with equal levels 
of protection seen with wild type zyPC (Figure 4.7). 
 
Loss of protection is not due to loss of coagulation in the 5A mutant 
While zyPC does not appear to require anticoagulant function in order to protect against 
metastasis, the loss of protection in the aPC-2A, -3A, and -5A mutants could still be due 
to loss of anticoagulant function if zyPC and aPC prevented metastasis through different 
mechanisms.  To examine this, we made the 5A mutations in the zyPC, as these protease 
domain mutations would have no adverse effect on the already non-existent anticoagulant 
function of zyPC.  Notably, zyPC-5A is unable to protect against tumor metastasis 
*** 
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(Figure 4.8), suggesting that the loss of anticoagulant function in the aPC-5A mutant is 
correlative, not causal, with the loss of metastasis protection. 
 
Reduction of tumor metastasis with overexpression of a/zyPC is not dependent on 
PAR-1-mediated cytoprotection 
The loss of anti-metastatic properties in the cytoprotective intact aPC-5A, -3A, -2A, and 
zyPC-5A mutants suggests that tumor protection with overexpression of a/zyPC is not 
through the cytoprotective pathway.  However, we sought to further confirm this using an 
additional mutant and PAR-1 deficient mice.   
 
aPC-E149A has a mutation in the protease domain, resulting in a signaling defective 
variant with severely reduced anti-inflammatory, anti-apoptotic, and cytoprotective 
functions 249.  This is despite normal binding of EPCR and cleavage of PAR-1.  When 
mice expressing aPC-E149A were challenged with B16F10 cells, they were equally 
protected against pulmonary lesions as mice expressing wild type aPC (Figure 4.9). 
 
To definitively determine if PC-mediated metastasis protection is PAR-1 dependent, we 
utilized PAR-1 knockout mice.  Knockout mice expressing zyPC were protected against 
tumor metastasis compared to PBS control knockout mice at a similar level of protection 
seen in zyPC-expressing heterozygous littermate controls, which are phenotypically the 
same as homozygous wild type mice (Figure 4.10A).  This is especially interesting given 
that PAR-1 knockouts develop less tumors than wild type mice (Figure 4.10B).  
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*** 
** 
Figure 4.9 Cytoprotective-deficient 
aPC-E149A retains the anti-
metastatic effect.  Mice were 
administered 5 x 1013 vg/kg AAV8-
maPC (red), -maPC-E149A (green), or 
PBS (blue) intravenously three weeks 
prior to intravenous injection of 2.5 x 
105 murine B16F10 cells.  Lungs were 
removed 21 days later and pulmonary 
tumor foci visible to the naked eye 
were quantified.  Significance is 
comparing the treated groups to the 
PBS control group.  Horizontal bars 
indicate mean ± SD.  ** p < 0.001, 
 *** p < 0.001. 
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Figure 4.10 The anti-metastatic effect of zyPC is not mediated through PAR-1 
cytoprotection.  (A) PAR-1 knockout mice were administered 5 x 1013 vg/kg AAV8-
mzyPC (green) or PBS (blue) and compared to PAR-1 heterozygous littermate controls 
that received 5 x 1013 vg/kg AAV8-mzyPC (purple) intravenously three weeks prior to 
intravenous injection of 2.5 x 105 murine B16F10 cells.  (B) Untreated PAR-1 knockouts 
or wild type littermate controls (females, pink; males, blue) received 2.5 x 105 murine 
B16F10 cells i.v.  In both experiments, lungs were removed 21 days later and pulmonary 
tumor foci visible to the naked eye were quantified.  Significance is comparing the 
treated groups to the PBS control group in A.  Horizontal bars indicate mean ± SD.   
* p < 0.05; ** p < 0.001. 
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Figure 4.11 Anti-metastatic protection is not mediated through AAV alone.  Mice 
were administered 5 x 1013 vg/kg AAV8-FIX with an early stop codon (AAV8-Null, 
orange) or PBS (blue) intravenously three weeks prior to intravenous injection of 2.5 x 
105 murine B16F10 cells.  Lungs were removed 21 days later and pulmonary tumor foci 
visible to the naked eye were quantified.  Significance is comparing the treated groups to 
the PBS control group.  Horizontal bars indicate mean ± SD.  ns, not significant. 
 
 
AAV does not protect against tumor metastasis 
To ensure that the anti-metastatic effect seen in these experiments was not due to AAV 
alone, mice were treated with an AAV null vector, which has an intact transgene with an 
early stop codon that prevents translation of protein.  No protection was seen with 
AAV8-Null (Figure 4.11), which is to be expected given that the vectors expressing the 
5A mutants were likewise not protective (Figures 4.2C, 4.3B, 4.8). 
 
IV. Discussion 
aPC is known to be protective against tumor metastasis.  While experimental models 
targeting thrombin are known to prevent metastasis, previous work by Van Sluis, et al. 231 
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indicated that endogenous aPC’s mechanism of protection did not involve the 
anticoagulation properties of aPC.  Furthermore, they argued that protection was 
mediated through the PAR-1 cytoprotective pathway.  Here, we sought to determine if 
the ability of aPC to reduce tumors in the context of overexpression of aPC worked 
through a similar mechanism.   
 
As with Van Sluis, et al., we did not see a loss of protection against metastasis with the 
anticoagulant defective aPC-L38D mutant.  However, there was a loss of protection with 
the aPC-5A mutant, which has a much greater reduction in anticoagulation, and loss of 
protection seemed to correlate with loss of anticoagulation, as seen with the intermediary 
-3A and -2A mutants.  However, we show here for the first time, that the zymogen PC, 
including an enzymatic site mutant that cannot be activated (zyPC-R15QS195A), which 
has no anticoagulant function, is equally protective, if not more so, and that zyPC-5A is 
also unable to protect against tumor metastasis.  This suggests that aPC and zyPC are 
working through the same mechanism—one that is independent of anticoagulation—and 
that the loss of anticoagulation in the 5A mutants is correlative, not causal.  It also 
suggests that the 5A mutants have lost an additional function, perhaps involving a 
protein-protein interaction that renders it unable to prevent metastasis.  Bezhuly, et al. 250 
demonstrated that treating an endothelial cell monolayer with recombinant human aPC in 
vitro prevented B16F10 adhesion to and transmigration through that monolayer.  This 
further supports the idea that zy/aPC is blocking some protein (perhaps receptor)-
mediated binding and extravasation by tumor cells. 
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Unlike Van Sluis, et al., the ability of supraphysiologic levels of zy/aPC to protect 
against metastasis was not dependent upon PAR-1 mediated cytoprotection.  Despite 
having intact cytoprotective function aPC-5A, -3A, and -2A were unable to prevent 
tumor metastasis like wild type aPC.  Additionally, the signaling deficient aPC-E149A 
was just as protective as the wild type aPC, and even completely knocking out PAR-1 did 
not prevent zyPC from protecting against metastasis.  There are two main reasons this 
discrepancy between our work and that of Van Sluis, et al. could exist.  First, it is likely 
that endogenous levels of cytoprotection are necessary for modulating metastasis.  
Without an effective endothelial barrier, tumor cell extravasation from the blood stream 
into new tissue sites might be unhindered (although, interestingly, knocking out PAR-1 
has the opposite effect).  However, it is possible that with the barrier intact, additional 
zy/aPC has no effect, as most EPCR is already occupied by zyPC and most PAR-1 
signaling already cytoprotective, so that pathway might be saturated.  The second 
explanation for the divergent results is that, like loss of anticoagulation in the 5A 
mutants, loss of coagulation with the antibody that renders aPC unable to protect against 
metastasis is correlative, not causal.  Interestingly, the antibody used by those authors that 
targets aPC alone does not inhibit the ability of the PC pathway to protect against 
metastasis, it is only the antibody that prevents both zyPC and aPC from binding to the 
endothelium that results in loss of anti-metastatic function.  While a lack of binding to 
EPCR and thus the endothelium would prevent cytoprotection, it is possible that this 
antibody is blocking zy/aPC competitive binding to an additional protein that tumor cells 
require access to in order to extravagate.  While plausible, this latter theory cannot 
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explain why stimulation of the S1P1 receptor, which is downstream of the PAR-1 
signaling pathway, reverses the effect of the antibody.  Thus, it is possible that the 
discrepancy between our data and theirs involves a combination of both scenarios. 
 
It is notable that zyPC is as effective—if not more so—as aPC in preventing metastasis.  
aPC half-life is only 15 minutes, and, as the no longer on the market drug Xigris 
demonstrated, aPC’s associated bleeding risks are potentially severe.  While it is true that 
many cancer patients may actually benefit from aPC’s anticoagulant properties, avoiding 
unwanted bleeds is a priority.  The risk of such bleeds with zyPC-R15QS195A is 
essentially zero, as the zymogen has no anticoagulant function, the active site mutation is 
redundant, and the thrombin-TM docking site mutation prevents the mutant from ever 
being activated.  Such a protein could be used for patients with high risk metastatic 
cancers, especially at the time of primary tumor resection, and would not require as 
frequent dosing given that zyPC has a much longer half-life (approximately 6 hours).  
Interestingly, doses of zyPC similar to those used here to confer protection against 
metastasis (~400%) have been given to healthy volunteers for a sepsis trial with no 
adverse effects 251.  However, if the mechanism of action can be found, it is possible that 
a small molecule inhibitor or antibody could be developed that would have an even 
longer half-life with minimal side effects.   
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CHAPTER 5 
SEARCHING FOR THE MECHANISM THROUGH WHICH PROTEIN C PREVENTS 
CANCER PROGRESSION 
 
 
I. Introduction 
In Chapter 4 we demonstrated that, despite suggestive literature, overexpression of aPC 
prevents tumor metastasis independent of aPC’s anticoagulant and cytoprotective effects.  
Importantly, we also demonstrated that zyPC is as protective as aPC and more feasible as 
a potential drug candidate, with a longer half-life and an increased safety profile 
associated with reduced risk of bleeding.  However, if the mechanism of action can be 
found, a small molecule inhibitor or antibody could be developed with even more 
appealing characteristics related to dosing frequency and side effects. 
 
Our work and the in vitro work of Bezhuly, et al. 252 suggest that this mechanism might 
involve competitively binding an endothelial cell surface receptor or protein, preventing 
tumor cell adherence and extravasation.  However, what this receptor might be is 
unknown, though previous work has demonstrated involvement of a few receptors in 
B16F10 tumor metastasis, including EPCR 252, PAR-4, and apoER2/LRP8 253.  Moreover, 
there are number of putative receptors that zy/aPC are thought to bind, including integrins 
on white blood cells and various additional platelet receptors 254.   
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It is also unknown if the competitive receptor binding is the only mechanism of action.  
For example, it is known that thrombin has a positive effect on tumor cell growth and 
angiogenesis 255, and so it is possible that zyPC can likewise inhibit these or other steps in 
cancer progression. 
 
Here, we begin to investigate some of these receptors’ involvement in the anti-metastatic 
ability of zyPC and attempt to determine which metastatic steps zyPC blocks.  
 
II. Materials and Methods 
Animals 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee at the Children's Hospital of Philadelphia.  Eight-week-old, male C57Bl/6 
mice were obtained from Jackson Laboratories.  NOD scid gamma (NSG) mice were 
obtained from the Children’s Hospital of Philadelphia breeding core.  EPCRlo mice on the 
C57Bl/6 background were generously provided by Charles Esmon, and were maintained 
at the Children’s Hospital of Philadelphia according to institutional guidelines. 
 
Cell culture 
B16F10 murine melanoma cells (ATCC) and 4T1 murine breast cancer cells (ATCC) 
were cultured in 1:1 DMEM/F12 (Gibco) supplemented with 10% fetal bovine serum 
(Gibco),1% antibiotic-antimycotic (penicillin-streptomycin-Fungizone, Gibco), and 1% 
L-glutamine at 37°C with 5% CO2.  Single cell suspensions were prepared for injection 
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by washing cells 3 times with phosphate buffered saline (PBS) followed by 3 µM EDTA 
and 3 more PBS washes.  Cells were then filtered, counted, resuspended in PBS, and 
stored on ice until injection. 
 
Tumor cell proliferation/growth assay 
293 producer lines expressing either canine FIX, murine zymogen protein C, or nothing 
were seeded in the upper chamber of a 3 µm pore transwell 6-well plate with the 
aforementioned growth media supplemented with vitamin K.  Two days later, B16F10 
cells were seeded into the lower half of the chamber.  24, 48, and 72 hours later, three 
wells of B16F10s per experimental group were counted in duplicate following treatment 
with Trypsin-EDTA to detach the cells. 
 
Tumor cell adhesion assay 
All wells were done in duplicate.  Wells of 6-well plates were pre-coated with 10 µg 
fibronectin, 6 µg Matrigel, 10 µg collagen or nothing in 1 mL PBS overnight at 4°C.  
Plates were then blocked with 1% BSA/PBS (with the exception of the control uncoated 
wells).  1 x 105 B16F10s that had been previously co-cultured with 293s expressing cFIX, 
mzyPC, or nothing were then seeded into the wells in 1 mL media (enriched with 4 µg 
recombinant mzyPC for the appropriate wells).  45 minutes later, plates were washed 3 
times with PBS to wash off non-adherent cells, and remaining cells were fixed for 15 
minutes in 70% methanol and then stained for 15 minutes with 5% crystal violet/20% 
methanol.  Plates were washed vigorously and repeatedly in deionized water to remove 
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excess crystal violet.  The stain was the released from the cells by adding 30% acetic 
acid, and color was quantified by reading absorbance at 590 nm.  ODs were normalized 
against the uncoated, unblocked control wells of the same time (co-cultured with 293, 
293-cFIX or 293-mPC) to account for small differences in the numbers of cells seeded 
per well. 
 
Recombinant AAV vector 
Production of AAV serotype 8 vectors was carried out by the Center of Cellular and 
Molecular Therapeutics’ vector core at the Children’s Hospital of Philadelphia as 
previously described 256.  The expression cassette contained wild type or mutant murine 
protein C with or without a PACE/Furin cleavage site motif encoded 3’ of the activation 
peptide (proteins with the PACE/Furin site added are cleaved intracellularly and secreted 
as activated protein C) behind three copies of the liver-specific ApoE enhancer region 
and the liver-specific human alpha-1 anti-trypsin (hAAT) promoter 256.  Null vector 
consisted of human factor IX with an early stop codon behind the same 
promoter/enhancer. 
 
Melanoma primary tumor model 
5 x 1013 vg/kg of AAV8 in 200 µL PBS was injected intravenously via lateral tail vein in 
mice on a C57Bl/6 background.  Three weeks later, blood was collected via tail bleeds 
into 3.8% sodium citrate, and plasma was removed and frozen for later analysis.  1 x 104 
B16F10 cells resuspended in 100 µL PBS were injected subcutaneously on the right 
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flank.  Tumor development was monitored, and after primary tumors were palpable in 
most mice (day 19) they were measured with calipers.  They were measured again on day 
25.  After 26 days mice were sacrificed by CO2 asphyxiation, blood was collected from 
the vena cava into 3.8% sodium citrate, and primary tumors were removed and weighed. 
 
Melanoma pulmonary metastasis model 
5 x 1013 vg/kg of AAV8 in 200 µL PBS was injected intravenously via lateral tail vein in 
mice on a C57Bl/6 background (or NSG mice).  Three weeks later, blood was collected 
via tail bleeds into 3.8% sodium citrate, and plasma was removed and frozen for later 
analysis.  2.5 x 105 B16F10 cells—unless otherwise indicated—resuspended in 200 µL 
PBS (1.25 x 106 cells/mL) were injected intravenously via lateral tail vein as previously 
described 257.  To block zyPC binding to EPCR, mice were first injected with 100 µg 
monoclonal rat anti-mouse EPCR blocking antibody (RMEPCR1560) 258 or an isotype 
control (both provided by Charles Esmon) in 0.5 mL PBS intraperitoneally 1 hour prior 
to B16F10 injection.  After 21 days mice were sacrificed by CO2 asphyxiation, blood was 
collected from the vena cava into 3.8% sodium citrate, and lungs were perfused with 4% 
paraformaldehyde via the trachea prior to removal and storage in 4% paraformaldehyde 
at 4°C.  Lung lobes were then separated and tumor foci visible with the naked eye were 
quantified by two independent, blinded observers. 
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Breast cancer pulmonary metastasis model 
5 x 1013 vg/kg of AAV8 in 200 µL PBS was injected intravenously via lateral tail vein in 
mice on a Balb/c background.  Three weeks later, blood was collected via tail bleeds into 
3.8% sodium citrate, and plasma was removed and frozen for later analysis.  1 x 104 4T1 
cells in 100 µL PBS were injected subcutaneously on the right flank.  As mice reached 
primary tumor endpoints (4-5 weeks later), they were sacrificed by CO2 asphyxiation, 
blood was collected from the vena cava into 3.8% sodium citrate, and lungs were 
perfused with India ink solution (15% v/v India Ink in dH2O) via the trachea prior to 
removal and storage in Fekete's solution at 4°C.  Lung lobes were then separated and 
white tumor foci visible with the naked eye were quantified by two independent, blinded 
observers. 
 
Quantification of murine zyPC  
Murine zyPC levels were determined with a traditional sandwich ELISA performed using 
monoclonal antibody AMPC-9071 rat anti-murine PC (Haematologic Technologies, Inc) 
at 10 µg/mL in PBS to coat and 2% BSA/0.05% Tween-20/PBS to block a 96 well-plate.  
Standards were recombinant murine zyPC provided by Giulia Pavani and Paris 
Margaritis diluted in 1:4 human protein C-deficient plasma (George King Bio-Medical, 
Inc):blocking buffer and samples were also diluted 1:4 in blocking buffer.  Polyclonal 
sheep anti-murine PC PAMPC-S (Haematologic Technologies, Inc) conjugated with HRP 
diluted 1:600 in blocking buffer served as the secondary antibody.  Plates were developed 
with OPD/hydrogen peroxide/sodium citrate solution. 
 
94 
 
Flow cytometry 
Human embryonic kidney 293 cells (negative control), murine Mile Sven 1 endothelial 
(MS-1) cells (positive control provided by Stephen Santoro), B16F10 cells, and 4T1 cells 
were harvested from monolayers with 3 µM EDTA, stained with rat anti-murine EPCR 
conjugated with FITC (StemCell Technologies), and histograms were generated with a 
BD Canto flow cytometer and FlowJo software (Treestar, Ashland, OR). 
 
Statistical analysis 
Statistics were run using GraphPad Prism (GraphPad Software Inc).  Graphs indicate the 
mean plus and minus the standard deviation.  Unpaired, one-tailed Welch's t-tests were 
used to compare treated groups to PBS control mice, and unpaired, two-tailed Welch's t-
tests were used to compare variant treated groups to positive control wild type zyPC 
treated groups.  P values <0.05 were considered statistically significant. 
 
III. Results 
Effect of zyPC on B16F10 tumor cell growth and adhesion 
B16F10 cells grown in the presence of a mzyPC-producing 293 line had neither their 
growth (Figure 5.1A) nor their adhesion to collagen, fibrinogen, Matrigel, or BSA-
blocked tissue culture wells (Figure 5.1B) negatively affected compared to B16F10 cells 
grown only in the presence of a non-producing 293 line.  A 293 line producing cFIX was 
used as an additional negative control, though interestingly adherence of the B16F10s 
was greatly improved in the presence of cFIX.  
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Figure 5.1 zyPC does not negatively affect B16F10 tumor cell growth or adhesion in 
vitro. (A) B16F10 melanoma cancer cells were seeded in the bottom of a 6-well transwell 
plate with 3 µm pores, with 293 producer cells stably expressing canine FIX (293-cFIX), 
murine zyPC (293-mPC), or nothing (293), and grown for 24, 48, or 72 hours before 
counting.  Wells were plated in triplicate, and each well was counted in duplicate.  (B) 
Plates were pre-coated with collagen, fibrinogen, Matrigel or nothing, then blocked with 
1% BSA (except for uncoated normalization wells) before plating B16F10s that had been 
grown in a transwell system with 293 producer cells stably expressing canine FIX (293-
cFIX), murine zyPC (293-mPC), or nothing (293) for more than one week.  Recombinant 
mzyPC was also spiked into the wells with B16F10s that had been grown with 293-mPC 
cells at a concentration of 4 µg/well.  45 minutes later, wells were washed and adherent 
cells were stained with crystal violet.  Retained stain was released with acetic acid and 
measured with a spectrophotometer at 590 nm.  Wells were done in duplicate and read in 
triplicate and then normalized against uncoated, unblocked wells. ns, not significant. 
 
 
 
B16F10 growth was likewise not inhibited in vivo.  Mice expressing mzyPC and PBS 
control mice had a primary B16F10 tumor seeded subcutaneously in their right flank.  
Primary tumor growth was monitored with calipers, and tumors were weighed at the end 
of the experiment.  There was no difference in the growth of the primary tumor in 
animals overexpressing mzyPC and wild type animals.  
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Figure 5.2 zyPC does not affect primary tumor growth in vivo. Mice were 
administered 5 x 1013 vg/kg AAV8-mzyPC (green) or PBS (blue) intravenously three 
weeks prior to subcutaneous injection of 1 x 104 murine B16F10 cells.  Primary tumors 
were measured with calipers on days 19 and 25, and then removed and weighed on day 
26.  Significance is comparing the treated groups to the PBS control group.  Horizontal 
bars indicate mean ± SD. 
 
 
EPCR is not required for zyPC protection against metastasis 
Previous work has shown that overexpression of EPCR decreases tumor metastasis in the 
B16F10 model, suggesting that PC-mediated protection is EPCR-dependent, although it 
was never directly shown.  In an attempt to address this question, we first utilized an anti-
EPCR antibody (RMEPCR1560) that prevents zyPC binding to EPCR.  Mice expressing 
zyPC and wild type mice were injected with blocking antibody, an isotype control, or 
PBS intraperitoneally 1 hour prior to B16F10 intravenous injection.  Wild type mice 
injected with the antibody did not develop tumors differently than wild type mice injected 
intraperitoneally with PBS, suggesting that the anti-EPCR antibody did not have an effect 
on metastatic pulmonary tumor formation.  zyPC-expressing mice injected with the anti-  
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Figure 5.3 zyPC anti-metastatic properties are not dependent on interaction with 
EPCR. (A) Mice were administered 5 x 1013 vg/kg AAV8-mzyPC (purple, green) or PBS 
(blue, orange) intravenously.  Three weeks later mice were injected intraperitoneally with 
PBS (blue), an anti-EPCR blocking antibody (orange, purple), or an isotype control 
antibody (green) one hour prior to intravenous injection of 2.5 x 105 murine B16F10 
cells.  Lungs were removed 21 days later and pulmonary tumor foci visible to the naked 
eye were quantified.  Significance is comparing the treated groups to the PBS + PBS 
control group, except where indicated with bars.  (B) Mice were administered 5 x 1013 
vg/kg AAV8-mzyPC (green), -mzyPC with the entire mFVIIIa Gla domain (mPC-
FVIIGlaAll, purple), -mzyPC with the first 22 amino acids of the mFVIIIa Gla domain 
(mPC-FVIIGla22, orange), or PBS (blue) intravenously three weeks prior to intravenous 
injection of 2.5 x 105 murine B16F10 cells.  Lungs were removed 21 days later and 
pulmonary tumor foci visible to the naked eye were quantified.  (C) EPCR conditional 
knockout mice (EPCRlo) were administered 5 x 1013 vg/kg AAV8-mzyPC (open circles) 
or PBS (upward triangles) and compared to EPCR-floxed homozygous littermate controls 
that received 5 x 1013 vg/kg AAV8-mzyPC (downward triangles) intravenously three 
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weeks prior to intravenous injection of 2.5 x 105 murine B16F10 cells.  (D) Untreated 
EPCRlo, heterozygous, or floxed mice received 2.5 x 105 murine B16F10 cells i.v. Lungs 
were removed 21 days later and pulmonary tumor foci visible to the naked eye were 
quantified.  Significance is comparing the treated groups to the PBS control group unless 
otherwise indicated.  Horizontal bars indicate mean ± SD.  ** p < 0.001;  *** p < 0.001; 
ns, not significant. 
 
 
 
EPCR antibody had significantly less tumors compared to wild type mice injected 
intraperitoneally with PBS or blocking antibody.  The reduction in tumor formation was 
similar to that seen in zyPC-expressing mice injected intraperitoneally with an isotype 
control antibody (Figure 5.3A). 
 
In order to confirm the results seen with the blocking antibody, we made zyPC mutants 
that would not bind to EPCR.  zyPC-EPCR binding is mediated through the Gla 
domain—specifically the first 8 amino acids, with the first 22 being associated with 
phospholipid membrane binding.  Therefore, mice expressing a wild type zyPC or a zyPC 
fusion molecule where either the entire Gla domain or just the first 22 amino acids of the 
Gla domain was swapped with mFVIIIa, which is known to not bind to mEPCR 259, 260, 
were used in the B16F10 model.  Both fusion molecules were equally protected against 
metastatic pulmonary tumor formation at comparable levels to wild type zyPC (Figure 
5.3B). 
 
Finally, we utilized EPCRlo mice to truly eliminate the involvement of EPCR.  These 
mice are generated through a conditional Cre targeting floxed ECPR alleles.  The Cre 
 
99 
 
excision is imperfect, leading to EPCRlo mice rather than complete knockouts.  EPCRlo 
mice expressing zyPC were protected against metastasis compared to PBS control 
EPCRlo mice, and at similar levels of protection seen in Cre-less floxed EPCR mice 
expressing zyPC (Figure 5.3C).  Interestingly, untreated EPCRlo mice generated from 
homozygous floxed alleles (KO), EPCRlo mice generated from a single floxed allele and 
a wild type allele (Het), and Cre-less floxed EPCR mice (F/F) all had similar levels of 
metastasis (Figure 5.3D).  This is surprising given previously published data that 
overexpression of EPCR decreases tumor metastasis; however, it is possible that enough 
EPCR remains as to not exacerbate tumor progression. 
 
zyPC anti-metastatic properties are not mediated through PAR-4 
Murine PAR-4 is a platelet PAR that, when knocked out, reduces the number of tumor 
metastasis.  Thus, it is possible that zyPC binding could mediate a similar effect.  
Therefore, we explored the effect of zyPC on metastasis in PAR-4 knockout mice, but 
found that, as with PAR-1 knockouts, zyPC was equally effective in preventing 
metastasis with or without PAR-4 (Figure 5.4). 
 
zyPC anti-metastatic properties are not mediated through β1/β3 integrin binding 
mzy/aPC has a QGD putative β1/β3 integrin binding site at amino acids 220-222 (RGD in 
haPC); when bound, aPC prevents neutrophil adhesion and migration 261.  Such a 
mechanism could easily by hijacked by tumor cells, and zy/aPC binding could block the 
needed receptors for tumor cell adhesion and invasion.  Therefore, we made a QGE   
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Figure 5.4 zyPC anti-metastatic 
properties are not dependent on 
interaction with platelet PAR-4. 
PAR-4 knockout mice were 
administered 5 x 1013 vg/kg AAV8-
mzyPC (orange) or PBS (blue) and 
compared to PAR-4 heterozygous 
littermate controls that received 5 x 
1013 vg/kg AAV8-mzyPC (green) 
intravenously three weeks prior to 
intravenous injection of 2.5 x 105 
murine B16F10 cells.  Lungs were 
removed 21 days later and 
pulmonary tumor foci visible to the 
naked eye were quantified.  
Significance is comparing the 
treated groups to the PBS control 
group.  Horizontal bars indicate 
mean ± SD.  * p < 0.05. 
 
 
 
mutant (zyPC-D222E) shown to ablate binding in haPC.  However, zyPC-D222E did not 
have reduced anti-metastasis abilities (Figure 5.5).    
 
Human zyPC is not as protective in a murine model of metastasis as murine zyPC 
Human and murine protein C share 69% homology, but human aPC has 6 times less 
anticoagulant activity and 10 times less neuroprotective effects, which likely require the 
anti-apoptotic properties of aPC 262.  This reduced functionality of hzyPC in mice in vivo 
is evident in the protection conferred in this B16F10 metastasis model (Figure 5.6).  
While still highly protective, the hzyPC mice formed an average of 20 times as many 
tumors as the mzyPC mice.  
 
101 
 
Figure 5.5 zyPC anti-metastatic properties 
are not mediated through the QGD 
putative β1/β3 integrin binding site on PC.  
Mice were administered 5 x 1013 vg/kg 
AAV8-mzyPC (squares), -mzyPC-D222E 
(triangles), or PBS (blue) intravenously three 
weeks prior to intravenous injection of 2.5 x 
105 murine B16F10 cells.  Lungs were 
removed 21 days later and pulmonary tumor 
foci visible to the naked eye were quantified.  
Significance is comparing the treated groups 
to the PBS control group.  Horizontal bars 
indicate mean ± SD.  *** p < 0.001. 
 
 
 
Figure 5.6 Human zyPC is not as 
protective as murine zyPC in a 
murine model of metastasis. Mice 
were administered 5 x 1013 vg/kg 
AAV8-mzyPC (green), -hzyPC 
(pink), or PBS (blue) intravenously 
three weeks prior to intravenous 
injection of 2.5 x 105 murine B16F10 
cells.  Lungs were removed 21 days 
later and pulmonary tumor foci visible 
to the naked eye were quantified.  
Horizontal bars indicate mean ± SD.  
* p < 0.05; *** p < 0.001. 
 
 
 
 
 
  
*** *** 
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Figure 5.7 zyPC is not protective in NSG 
mice when tumor load is high.  NOD scid 
gamma mice were administered 5 x 1013 
vg/kg AAV8-mzyPC (green) or PBS (blue) 
intravenously three weeks prior to 
intravenous injection of murine B16F10 
cells.  Lungs were removed 21 days later 
and pulmonary tumor foci visible to the 
naked eye were quantified.  Horizontal bars 
indicate mean ± SD.  ns, not significant. 
 
 
NSG mice are not protected against metastasis with zyPC when tumor load is high 
In order to determine if the anti-metastatic properties of zyPC are dependent upon direct 
interaction with immune cells, we utilized the NOD scid gamma mouse line.  NSGs are 
lacking mature B and T cells, NK cells, and complement and have defective dendridic 
cells and macrophages.  As would be expected, these mice could not tolerate the normal 
dose of 2.5 x 105 B16F10s, and so were given a lower dose of 6.5 x 104.  Despite this 
lower dose, the tumor load in all animals was still very high, and there was no difference 
seen in the animals expressing zyPC compared to the control animals (Figure 5.7). 
 
zyPC-mediated anti-metastasis protection is not limited to B16F10 melanoma cells 
While there is an apparent lack of direct effect on B16F10 cell growth (Figure 5.1A, 
5.2), adhesion (Figure 5.1B), and transmigration 252, it is possible that the anti-metastatic 
effect is cancer cell type specific, either by a yet undiscovered direct tumor effect or 
because of differing tumor cell adhesion and/or extravasation receptors.  Thus, we 
explored whether zyPC would be protective in a model of metastatic breast cancer.  
 
103 
 
Figure 5.8 zyPC is protective against 
metastasis in the 4T1 breast cancer 
model.  Mice were administered 5 x 1013 
vg/kg AAV8-mzyPC (green) or PBS 
(blue) intravenously three weeks prior to 
subcutaneous injection of 1 x 104 murine 
4T1 cells.  As mice reached experimental 
endpoints related to primary tumor size 
and animal wellness, they were sacrificed 
and lungs and primary tumors removed.  
Pulmonary tumor foci visible to the naked 
eye were quantified.  Horizontal bars 
indicate mean ± SD.  * p < 0.05.  
 
 
Unlike with the B16F10 melanoma model, 4T1 cells are subcutaneously injected to form 
a primary tumor on the animal’s flank, which becomes metastatic upon reaching a large 
enough size.  That primary tumor will then continuously seed new metastases unless 
resected, making it a highly aggressive model of metastasis.  As such, the pulmonary 
tumor load in these animals was quite high.  However, we did still see a slight reduction 
in the number of metastases in the lungs of the zyPC treated animals (Figure 5.8).  
Importantly, there was no difference in the size or progression of the primary tumors 
between the groups (data not shown). 
 
IV. Discussion 
Our in vitro and primary tumor work demonstrates that zyPC does not have a direct effect 
on B16F10 cell growth, nor does it impact B16F10 adhesion to proteins of the basement 
membrane.  This is comparable to previous work that demonstrated aPC could only 
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prevent B16F10 cell adhesion to and transmigration across an endothelial cell monolayer 
when the endothelial cells—not the B16F10s—were pre-treated with aPC 252.  
Collectively, these data suggest that the anti-metastatic properties of zy/aPC are limited 
to affecting the host, not the tumor cells. 
 
This, in conjunction with the data shown in Chapter 4, further implies that the mechanism 
of protection is likely to be via competitive blocking of an endothelial receptor or 
membrane protein that prevents B16F10 tumor cell adhesion and/or extravasation.  
Unfortunately, the potential receptors are endless, so we chose to focus on receptors 
already identified as putative zy/aPC binding 254.   
 
The first receptor we investigated was the endothelial protein C receptor, as this had 
already been demonstrated as being involved in the zy/aPC anti-metastatic pathway 252.  
Overexpression of EPCR in Tie2-EPCR transgenic mice had led to a massive reduction 
in the number of pulmonary tumor foci formed after B16F10 cell injection.  However, we 
demonstrated through three different methods that zyPC-based protection is not 
dependent upon EPCR binding, suggesting that the overexpression of EPCR is having a 
different effect than previously thought.  One possible explanation is that with more 
EPCR available for binding, plasma levels of zyPC may go up, and it is these increased 
levels that facilitate reduced metastasis. 
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We also attempted to explore the necessity of the immune system and white blood cell 
receptors on the anti-metastatic properties of PC.  We successfully demonstrated that 
binding to β1 and/or β3 receptors is not required, but our results with the NSG mice were 
less clear.  While we did not see zyPC-mediated protection in these mice, it is possible 
that the high tumor load exceeded the ability of zyPC to modulate metastasis.  Thus, the 
experiment should be repeated with even lower B16F10 cell doses. 
 
Despite that fact that previous work has shown involvement of PAR-4 in B16F10 
metastasis, we did not see a loss of ability of zyPC to protect against metastasis in PAR-4 
knockout animals.  This is one of just a couple of platelet-related receptors that zy/aPC is 
believed to bind, the other two being platelet receptors on the endothelium: MAC-1 and 
apoER2 (also known as LRP8).  LRP8 was recently shown to be involved in B16F10 and 
human melanoma cell extravasation through mutual apoE binding by apoER2 on the 
vessel wall and LRP1 on the cancer cells.  Should PC somehow interfere with this 
apoER2/apoE or apoE/LRP1 binding, it is possible that this is the mechanism through 
which the protein C pathway prevents metastatic cancer progression.  
 
We also showed that hzyPC has reduced anti-metastatic effects compared to mzyPC in 
the murine model (approximately 20 times less), although the number of tumors in the 
hzyPC-expressing mice compared to untreated animals still reflected an 88% reduction in 
the number of metastasis.  This reduced efficacy of hzy/aPC is paralleled in the reduced 
anticoagulant function, which is thought to be due to reduced PS binding, seen in vivo in 
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mice and in vitro in murine plasma, as well as in the reduced neuroprotective effects seen 
in ischemic stroke, which again is thought to be due to reduced receptor binding.  Thus, 
the loss of anti-metastatic properties with species specificity further supports the idea that 
zy/aPC protection against cancer progression requires protein-protein interaction, rather 
than, for example, catalytic function. 
 
Finally, we demonstrate that the protection seen in our work and the previously published 
work of others 252, 231 utilizing B16F10s is not restricted to the melanoma cancer cell 
model.  This provides hope that, should a pharmacologic intervention ever result from 
these studies, it could potentially benefit a wider range of patients than just those with 
cancers of the skin.  Ultimately, though, for such a product to reach the market, more 
must be understood about the mechanism of action of the protein C pathway’s ability to 
prevent cancer progression by blocking tumor metastasis.  
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
The field of gene therapy is currently undergoing a resurgence after falling out of favor 
with the death of Jesse Gelsinger in 1999 and issues with childhood leukemia in the early 
2000s.  In 2012, Glybera, an AAV1 expressing lipoprotein lipase, was approved in 
Europe, making it the first gene therapy product licensed in the Western world.  There 
have been a number of additional promising and successful gene therapy clinical trials in 
the last few years, from hemophilia to Leber’s congenital amaurosis to cancer, and it is 
expected that a number of new products will be joining Glybera in the near future. 
 
This work demonstrates that gene therapy with coagulation protein transgenes has the 
potential to treat hemophilia A (Chapter 2) and B (Chapter 3) patients currently excluded 
from clinical trials for inhibitors by tolerization and immune modulation following liver-
directed AAV gene therapy, as well as modulating cancer progression through inhibition 
of metastasis (Chapters 4 and 5). 
 
Hemophilia, gene therapy, and the immune system 
Hemophilia has a nearly 15-year history of gene therapy, with promising results in the 
last few years following liver-directed gene therapy for HB with AAV8 263.  However, 
even those promising trials have required courses of prednisolone in most patients 
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receiving efficacious vector doses in order to prevent anti-AAV capsid CD8+ cytotoxic T 
cells from destroying the transduced hepatocytes and resulting in loss of transgene 
expression.  In Chapter 3, we demonstrated that vector doses for HB can be dramatically 
lowered with no loss of FIX activity by utilizing the naturally occurring, hyper-functional 
FIX-Padua as the transgene, potentially allowing for vector doses low enough to prevent 
immune activation and avoid the use of steroids.  Importantly, we demonstrated that this 
increased specific activity does not increase the risk of either thrombophilia—even in a 
dog with nearly 300% FIX activity—or transgene-product immunogenicity, despite the 
point mutation.  This indicates that FIX-Padua is as safe as the wild type FIX transgene 
that has been used in numerous clinical trials with no adverse effects to date, and that 
moving FIX-Padua into people is a reasonable proposal.  One such clinical trial with 
AVV-FIX-Padua is currently underway and another is in the planning stages.  Hopefully 
the results of the preclinical work done by our lab and others with this novel transgene 
will be mirrored in human subjects, greatly increasing the efficacy and safety of HB gene 
therapy.   
 
While our lab is currently working to determine the mechanism responsible for the 
heightened specific activity of FIX-Padua, the work shown in Chapter 3 has been a proof-
of-principle that modifications to the transgene that result in higher expression or activity 
might be utilized to overcome the vector-dose-dependent, anti-capsid immune response.  
For example, if a corresponding modification can be made in FIX’s cofactor, FVIII, that 
could have profound impacts for HA gene therapy as well.  Additionally, our lab is 
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exploring other FVIII variations seen in cFVIII that results in higher secretion compared 
to hFVIII.  As with the studies done here, any such modifications must be rigorously 
tested for safety, especially with relation to immunogenicity. 
 
In all clinical trials to date, hemophilia patients with inhibitors have been excluded.  
However, as shown in Chapters 2 and 3, liver-directed AAV gene therapy has the ability 
to induce tolerance to the transgene, even in the context of a pre-existing, ongoing 
immune response to that transgene.  It is possible, therefore, that the risk-benefit analysis 
for inclusion in a gene therapy trial might actually be slanted toward preferentially 
including inhibitor patients, who otherwise face a grueling and expensive ITI protocol.  
Beyond the world of hemophilia, many diseases could potentially benefit from 
AAV/liver-driven transgene tolerization.  For example, autoimmune diabetes has been 
prevented in NOD mice following AAV expression of the beta-cell autoantigen glutamic 
acid decarboxylase 65 peptide GAD(500-585) from the liver 264.  A number of additional 
autoimmune diseases such as autoimmune hemolytic anemia, multiple sclerosis, 
autoimmune thrombocytopenic purpura, and rheumatoid arthritis have known 
autoantigen targets that do not necessarily require nor would they necessarily benefit 
from straight transgene replacement.  In these instances, liver-restricted expression and 
resulting retolerization could halt disease progression and potentially even prevent 
disease entirely.  
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Gene therapy induced tolerance can also benefit a group of patients with genetic diseases, 
such as metabolic disorders like Pompe disease, where enzyme replacement therapies 
(ERT) currently on the market are ultimately inhibited by the development of neutralizing 
antibodies to the infused protein.  While this scenario is similar to the development of 
inhibitors in hemophilia patients, up to 90% of juvenile patients will develop antibodies 
to ERT, and there is no standard ITI protocol for Pompe disease.  In the few instances 
where a case is successfully treated it is cause for a New England Journal of Medicine 
paper 265.  Unfortunately, it takes extremely high levels of enzyme to ameliorate the 
disease phenotype in Pompe—well outside the range currently achievable with gene 
therapy—which would traditionally make it a poor candidate for current gene therapy 
practices.  However, these patients would benefit highly from ITI and, as such, AAV 
liver-directed gene therapy, for the sole purpose of tolerizing the patient to the 
pharmacologic product as this would keep their ERT efficacious. 
 
The question remains how, exactly, AAV expression in the liver can induce and maintain 
tolerance to the transgene.  As was discussed at length in Chapter 1, it is likely a 
multifaceted immune response, with data in murine models pointing to anergy, T cell 
deletion, and Treg induction.  In Chapter 2 we showed that in dogs with pre-existing 
inhibitors, CD4+CD25+FoxP3+ T cells expanded 1 to 2 weeks after AAV8-FVIII vector 
administration and immediately prior to disappearance of FVIII-specific antibodies.  This 
expansion was not seen in dogs without pre-existing inhibitors and was delayed in a dog 
that developed a transient inhibitor after gene therapy.  While identification of these T 
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cells as FVIII-specific Tregs is impossible given current technologies, the timeline in 
conjunction with what is known from the aforementioned previous experience in 
transgenic mice suggests that these could be FVIII CD4+ induced Tregs.   
 
Furthermore, in Chapter 3 we saw a noticeable lack of IL-2, a sign of Treg activity, in the 
FIX inhibitor dog following AAV8-FIX-Padua gene therapy, despite an ongoing, pro-
inflammatory, Th2 immune response as indicated by elevated levels of GM-CSF, IL-15, 
IL-6, and IL-18.  Additionally, IL-10—a classic Treg tolerogenic cytokine—levels were 
highest 2-4 weeks after vector administration (around the time we saw the increased 
frequency of CD4+CD25+FoxP3+ T cells in the FVIII inhibitor model and correlating 
with the elimination of anti-FIX neutralizing antibodies).  IL-10 also began to rise again 
immediately following challenge with FIX concentrate, suggesting further suppression of 
an anti-FIX immune response was required.  
 
Interestingly, IFN-γ also peaked with IL-10.  IFN-γ is traditionally considered to be a Th1 
and CD8+ T cell cytokine; however, the lack of correlating IL-2 and TNF-α is surprising 
were that the case.  While it is possible this is indicative of an anti-FIX cytotoxic T cell 
response, this is further unlikely given that inhibitors are traditionally thought of as Th2 
and antibody driven.  Instead, there is some indication in the literature (see Chapter 2 
discussion) that conversion of CD4+ T cells into induced Tregs in the periphery requires 
and/or produces IFN-γ.  If this is the case here, the duel peaks at weeks 2-4 and 
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immediately following challenge with FIX concentrates further supports the idea that 
Tregs are induced following AAV administration and again following challenge. 
 
TNF-α levels were low throughout and similar cytokine profiles were not seen in two 
non-inhibitor dogs, indicating that this is not simply an anti-vector immune response. 
 
Further canine immunology reagents must be developed and additional studies done to 
fully understand the mechanisms by which AAV-directed transgene expression in the 
liver is able to induce tolerance in the context of a pre-existing and ongoing immune 
response against the transgene.  Such understanding would allow researchers to more 
fully comprehend the risks and rewards involved in utilizing gene therapy for ITI as well 
as potentially provide translatable practices to current recombinant protein-based ITI 
protocols. 
 
Activated and zymogen protein C and cancer metastasis 
While much about the protein C pathway has been well characterized, there is just as 
much that remains hotly debated.  Even the well-established anticoagulant and 
cytoprotective functions have lingering mechanistic questions (Does aPC really cleave 
FVIIIa or PAR-1 in vivo?).  Much less is understood about any potential functionality of 
zyPC, which is often ignored in the literature, considered to be just a proenzyme waiting 
to be activated.  In this sea of ambiguity, it was discovered that aPC has the ability to 
reduce tumor metastasis, so researchers endeavored to determine the mechanism of action 
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by focusing on the most well understood and the most likely to be involved aPC 
functions: anticoagulation and cytoprotection.   
 
While there is overwhelming evidence that coagulation enhances metastasis and 
supporting data suggesting that inhibiting coagulation prevents metastasis, Van Sluis et. 
al. 266 showed compelling data that inhibiting the anticoagulant function of endogenous 
aPC with an antibody that selectively binds aPC rather than zyPC but that left the 
cytoprotective function intact did not worsen the number of pulmonary metastatic lesions 
formed 267.  Conversely, knocking out both the anticoagulant function and cytoprotective 
function via an antibody that prevents PC binding to cell membranes (likely by blocking 
binding to EPCR) increased the number of metastatic tumors formed.  The authors 
interpreted this as an indication that anticoagulant function is not necessary for the anti-
metastatic properties of aPC, and that the cytoprotective function is.  Furthermore, they 
were able to reduce the number of tumors formed in animals treated with the second 
antibody back to baseline levels by using an S1P1 agonist, demonstrating that aPC’s 
protective properties function through the PAR-1/SphK-1/S1P1 receptors pathway.  In 
addition, Bezuhly et al. 268 showed that overexpressing EPCR in transgenic mice 
decreased the number the metastases, though they did not explore how EPCR 
overexpression affected zy/aPC levels.  Collectively, these two papers suggest that 
endogenous aPC protects against metastasis via the PAR-1-mediated cytoprotective 
effect.     
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However, this was not what we saw in our model.  Knocking out the cytoprotective effect 
(E149A) did not diminish a/zyPC’s anti-metastatic properties, nor did knocking out PAR-
1 in the mice.  Additionally, the 2A, 3A, and 5A mutants, which retain cytoprotective 
function, had reduced abilities to protect against metastasis.  This suggests that 
endogenous levels of zy/aPC cytoprotection is important in modulating tumor 
progression, but that additional cytoprotection is of no benefit for preventing tumor 
metastasis.  Alternatively, it is possible that the antibody used by Van Sluis et al. 267 
blocks more than just the cytoprotective and anticoagulant effect of zy/aPC.  
 
We also demonstrated that, despite previously published work to the contrary, EPCR 
binding is not necessary for the anti-metastatic effect (blocking antibodies, EPCRlo mice 
and Gla domain swaps), suggesting that perhaps the Tie2-EPCR transgenic mice are 
protected due to another mechanism, such as an increase in zyPC levels in response to 
more receptor available for binding. 
 
Finally, we showed that aPC is not working through its anticoagulant function (aPC-
L38D, zyPC, zyPC-R15Q, zyPC-S195A, zyPC-R15QS195A), even though it is known 
that blocking coagulation in mice can reduce metastasis (see Chapter 1 for thorough 
discussion). 
 
After eliminating the most likely mechanisms of protection, we began examining putative 
PC-binding receptors.  αMβ2 and β1/β3 integrins are involved in white blood cell adhesion, 
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while apoER2 and GP1bα are involved in platelet adhesion 269.  PAR-4 is also a platelet 
receptor.  We have eliminated the involvement of PAR-4 (knockout mice) and β1/β3 
integrins (zyPC-D222E).  NSG mice showed no reduction in tumor metastasis with 
treatment, but the tumor load was extremely high and may simply have been too high for 
treatment to be effective.  Going forward, the NSG mice experiment should be repeated 
with an even lower dose of B16F10s to further determine if there is involvement of the 
immune system.  Antibodies and knockout mice for GP1bα and LRP8/apoER2 knockout 
mice are available and should be utilized. 
 
Throughout this work we refer to the ability of the protein C pathway to modulate tumor 
progression as affecting metastasis.  The lack of inhibition of primary tumor and in vitro 
cell growths support this, as does work by Bezuhly et al that demonstrated reduced 
transendothelial migration following B16F10 exposure to rhaPC 268.  Interestingly, we did 
not show reduced adhesion of B16F10s to collagen, fibrinogen, or Matrigel, suggesting 
that the loss of adhesion seen by Bezuhly et al was due to blocking something on the 
bEnd.3 cells rather than on the B16F10s.  This had been suggested by those authors as 
well, as pre-treating B16F10s with rhaPC did not prevent binding to bEnd.3 monolayers 
like pre-treating the bEnd.3 cells did.  Likewise, they also showed that pre-treatment of 
the bEnd.3 cells but not the B16F10 cells was able to reduce transmigration across the 
bEnd.3 monolayer and transwell membrane.  Collectively, these data suggest that the 
ability of zy/aPC to prevent cancer progression is truly through limiting the metastatic 
pathway by acting on the host rather than directly on the tumor cells. 
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Previously, the potential of using aPC to combat cancer progression seemed unlikely 
given its extremely short half-life (approximately 15 minutes) and the removal of Xigris, 
recombinant human activated protein C intended for use in sepsis treatment, from the 
market after failed efficacy and bleeding risks.  However, the zymogen has a 6 hour half-
life and could be further extended as progress has been made in the hemophilia market 
with modifications such as PEGylation to greatly increase the half-life of clotting factors.  
Additionally, zyPC, and especially zyPC-R15QS195A, would not have the same risk of 
bleeds as aPC.  Interestingly, injections of recombinant human zyPC into septic, but 
otherwise healthy, volunteers at fold levels over baseline similar to those seen here 
following gene therapy caused no adverse effects 270.  It is possible that treatment of 
patients with cancers known to be metastatic, especially at the time of primary tumor 
resection, could have a disease progression benefit for patients. 
 
While recombinant zymogen PC can be produced and marketed, if the mechanism of 
action of metastasis prevention can be found it is possible that a longer acting small 
molecule or antibody could be produced.  In the interim, it is also possible that gene 
therapy with AAV to express zyPC-R15QS195A could be as protective in human 
subjects as it is in animal models.  However, potential side effects due to long-term 
competition with wild type zyPC should be explored, and any trials conceived should 
target patients with the highest risk of mortality due to cancer types with known 
tendencies to quickly metastasize so as to ensure a proper risk-benefit ratio. 
 
 
117 
 
Closing Remarks 
The potential applications for gene therapy seem endless, and range dramatically from 
life-saving neonatal therapies to address fatal fetal anomalies to elective treatments to 
correct male-pattern baldness.  As this dissertation has demonstrated, gene therapy has a 
place not only in treating monogenetic inherited disorders by solely replacing a mutant 
gene but also in manipulating the immune system and in appropriating normal 
physiologic processes to new ends. 
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APPENDIX A 
ABBREVIATIONS 
 
 
a, activated 
aPC, activated protein C 
aPTT, activated partial thromboplastin time 
AAV, adeno-associated virus or adeno-associated viral vectors 
BDD, B-domain deleted 
BU, Bethesda units 
c, canine 
CRM, cross reacting material 
EGF, epidermal growth factor 
ELISA, enzyme-linked immunosorbent assay 
EPCR, endothelial protein C receptor 
ERT, enzyme replacement therapy 
F, factor 
GM-CSF, granulocyte macrophage colony-stimulating factor 
h, human 
HA, hemophilia A 
hAAT, human alpha-1 anti-trypsin 
HB, hemophilia B 
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HC, heavy chain (of FVIII) 
HD, high dose 
IFN, interferon 
IL, interleukin 
ITI, immune tolerance induction 
ITR, inverted terminal repeat 
iTreg, induced Treg 
LC, light chain (of FVIII) 
LD, low dose 
m, murine 
MD, mid dose 
MS-1, murine Mile Sven 1 endothelial cells 
NAb, neutralizing antibody 
NFκB, nuclear transcription factor κB 
NK, natural killer (cell) 
NSG, NOD scid gamma mice 
PAR, protease activated receptor 
PBMCs, peripheral blood mononuclear cells 
PBS, phosphate buffered saline 
PS, protein S 
r, recombinant 
S1P, sphingosine-1-phosphate 
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S1P1, S1P receptor-1 
SphK-1, sphingosine kinase-1  
TAT, thrombin-antithrombin complex 
TNF, tumor necrosis factor 
TBG, human thyroxine binding globulin 
TF, tissue factor 
TM, thrombomodulin 
TEG, thrombelastography 
UAB, University of Alabama at Birmingham 
UNC, University of North Carolina (at Chapel Hill) 
VTE, venous thromboembolism 
WBCT, whole blood clotting time 
zyPC, zymogen protein C 
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APPENDIX B 
DOGS 
 
 
HA dogs 
K01, pre-existing cFVIII inhibitors from UNC, treated with 2.5 x 1013 vg/kg of AAV8-
cFVIII-LC and 2.5 x 1013 vg/kg AAV8-cFVIII-HC i.v. 
K03, pre-existing cFVIII inhibitors from UNC, treated with 2.5 x 1013 vg/kg of AAV8-
cFVIII-LC and 2.5 x 1013 vg/kg AAV8-cFVIII-HC i.v., FVIII coverage at the 
time of vector administration 
L44, pre-existing cFVIII inhibitors from UNC, treated with 2.5 x 1013 vg/kg of AAV8-
cFVIII-LC and 2.5 x 1013 vg/kg AAV8-cFVIII-HC i.v. 
L51, inhibitor prone from UNC, developed transient inhibitors, treated with 2 × 1013 
vg/kg of AAV8-cFVIII-BDD single chain i.v. 
Linus, inhibitor prone from UNC, treated with 6.0 × 1012 vg/kg of AAV8-cFVIII-HC and 
6.0 × 1012 vg/kg AAV8-cFVIII-LC i.v. 
M06, inhibitor prone from UNC, treated with 4 × 1013 vg/kg AAV8-cFVIII-BDD single 
chain i.v. 
Wembley, pre-existing hFVIII inhibitors from Queen’s University, large anamnestic 
response, treated with 2.5 x 1013 vg/kg of AAV8-cFVIII-LC and 2.5 x 1013 vg/kg 
AAV8-cFVIII-HC i.v. 
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HB dogs 
Trex, inhibitor-prone from UAB, treated with 3 x 1012 vg/kg AAV8-cFIX-Padua i.v.  
Wick, inhibitor prone from UAB, treated with 1 x 1012 vg/kg AAV8-cFIX-Padua i.v. 
Wiley, pre-existing hFIX inhibitors from UAB, treated with 3 x 1012 vg/kg AAV8-cFIX-
Padua i.v. 
